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Abstract 
The prostate epithelium is defined in terms of a hierarchical structure, where each cell 
type can differentiate into the next cell in the lineage until terminally differentiated 
luminal cells are formed. Androgen receptor (AR) appears to be essential for 
differentiation of basal to luminal cells. However previous research was predominantly 
conducted on mouse models, which have a different epithelial structure and therefore 
this project focussed on 3D models of human prostate cell lines. This project aims to 
knockout (KO) AR in BPH-1 PPmO cells (benign cell line with fluorescent 
differentiation indicator) and P4E6 cells (localised cancer cell line) using CRISPR/Cas9, 
then to generate tools with which to investigate the effects of AR KO on prostate 
differentiation. The hypothesis was that AR expression is essential for cell 
differentiation during prostate cancer (PCa) development. Copy number analysis 
determined that BPH-1 PPmO contains three copies of AR, whilst P4E6 contains one 
copy. This allowed for the generation of P4E6 homozygous and BPH-1 PPmO 
heterozygous clones. The CRISPR/Cas9 lentivirus successfully created edits in both cell 
lines, with the highest efficiency occurring in P4E6 cells. Analysis via qRT-PCR 
confirmed that AR was successfully knocked out in both the BPH-1 PPmO and P4E6 
clones. Growing prostate basal cells in 3D culture induces differentiation and the 
expression of AR, by mimicking the prostate in vivo. The differentiation indicator only 
fluoresced in wild-type (WT) BPH-1 PPmO spheroids, indicating AR may indeed be 
required for differentiation. However the survival of ARKO clones demonstrated that 
AR is not essential for basal cell survival. Future work should focus on further 
optimising differentiation via the addition of retinoic acid (RA) to spheroids and 
engrafting the edited cell lines into immunocompromised mouse models. This project 
has generated a wide selection of ARKO models which are suitable for the 
investigation of the role of AR during PCa development.  
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1. Introduction  
1.1 The Prostate Gland 
The prostate is a male exocrine gland that is situated around the urethra and beneath 
the bladder. The prostate is composed of epithelial acini that are surrounded by a 
fibromuscular stromal network. Its primary role is to produce prostatic fluid, which 
contributes to the formation of semen. It consists of three main areas; the central 
zone, the peripheral zone and the transitional zone (Figure 1.1). The peripheral zone 
is where 70% of prostate cancer (PCa) arises, with 20% occurring in the transitional 
zone, and 10% in the central zone (Levine & Haggitt, 1989). The transitional zone is 
also where the majority of benign prostatic hyperplasia (BPH) occurs (McNeal, 1981). 
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Figure 1.1: The prostate gland. The prostate consists of three zones: the transition, peripheral 
and central zones. It is found below the bladder and surrounding the urethra (Adapted from 
Oldridge et al., 2012). 
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1.1.1 Development of the Prostate 
The urogenital sinus in embryos can differentiate into either the prostate in males, or 
the vagina in females, at approximately 9 weeks of gestation in humans (Toivanen and 
Shen, 2017). This sexual dimorphism is controlled by the presence of androgens which 
trigger epithelial budding to form the prostate (Bryant et al., 2014). Androgen 
signalling from the urogenital sinus mesenchyme (UGM) to the urogenital sinus 
epithelium (UGE) initiates the formation of ducts, which then mature to form a ductal 
network. Currently there are two main hypotheses to suggest how androgens are able 
to initiate epithelial induction and budding: the smooth muscle model and the 
andromedin model (Toivanen and Shen, 2017). 
The smooth muscle model suggests that androgen signalling controls the 
differentiation of smooth muscle around the prostate ducts; hence stopping epithelial 
budding in these areas. Therefore, in this model, androgens from the mesenchyme 
have an indirect effect on the development of epithelial tissue. The andromedin 
hypothesis, on the other hand, suggests that a signalling factor called an andromedin 
binds to the androgen receptor (AR) found within the UGM, and this directly triggers 
epithelial budding in the UGE (Figure 1.2). Currently it is thought that andromedins 
could be fibroblast growth factor (FGF) or Wnt, however there is currently not enough 
evidence to confirm the possibility of either of these ligands to be related to 
androgens (Toivanen and Shen, 2017). 
As well as androgen signalling, retinoic acid (RA) can also initiate bud development in 
the UGS. RA is a ligand that binds to a RA receptor (RAR), which is found in the 
nucleus. RAR then binds to retinoic acid response elements (RARE) in DNA, along with 
retinoic X receptors (RXR), to control gene expression. Interestingly, if androgens are 
not present, RA is still able to induce prostate development. Also, if aldehyde 
dehydrogenase (ALDH), which catalyses the formation of RA, is inhibited, prostate 
buds cannot form in UGS explants, despite the presence of dihydrotestosterone 
16 
(DHT). This suggests that both androgens and RA work together to initiate bud 
formation and prostate development in the UGE (Bryant et al., 2014, Rivera-Gonzalez 
et al., 2012).  
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Figure 1.2: Predicted models for prostate development. (A) The smooth muscle model 
suggests androgens have an indirect effect on epithelial budding by controlling the 
development of the smooth muscle. (B) The andromedin model suggests andromedins bind 
to AR in the UGM to directly induce epithelial budding (Adapted from Toivanen and Shen, 
2017). 
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1.1.2 The Adult Prostate Epithelium  
The epithelium contains a variety of cell types: prostate stem cells (SC), 
neuroendocrine cells, transit amplifying (TA) cells, committed basal (CB) cells and 
luminal cells. The basal compartment is formed of SCs, TA and CB cells which are 
attached to the basement membrane (BM) (Figure 1.3A) (Maitland, 2013). The 
prostate epithelium can be described in terms of an hierarchical pathway, in which 
each type of cell can differentiate into the next cell in the lineage until the terminally 
differentiated luminal cells are formed (Figure 1.3B). However, there is a degree of 
plasticity within this hierarchy, because TA cells are potentially able to maintain 
multipotency and cycle back to form SCs (Isaacs and Coffey, 1989). 
Luminal cells make up the majority of adult prostate epithelium (60%) (Packer and 
Maitland, 2016). They are secretory and terminally differentiated cells that are 
dependent on androgen signalling for survival. They secrete prostate specific antigen 
(PSA) and prostatic acid phosphatase (PAP) (Myers and Grizzle, 1996). Luminal cells 
can be characterised by high expression of AR (Table 1.2) (Prins et al., 1991) the  
presence of cytokeratins CK8 and CK18 (Sherwood et al., 1990), NKX3.1 (He et al., 
1997) and CD57 (Liu et al., 1997) (Table 1.1). 
Basal SCs asymmetrically divide, allowing for the differentiation into two groups of 
basal cells: CB cells and TA cells (also referred to as intermediate cells) (Oldridge et al., 
2012). Together they make up 40% of the epithelium (Packer & Maitland, 2016). Both 
CB and TA cells do not rely on androgen signalling for survival and hence express 
either no, or low levels of AR (Table 1.2) (Kyprianou and Isaacs, 1988). Despite this, 
some TA cells have been shown to be androgen responsive which enables them to 
increase the number of AR dependent luminal cells (Collins et al., 2005). CB cells 
express different cytokeratins (CK5 and CK14) to luminal cells (Sherwood et al., 1990) 
as well as p63 (Liu et al., 1997) (Table 1.1). Some TA cells display both luminal and CB 
cell markers, resulting in an intermediate phenotype (Table 1.1) (Verhagen et al., 1992, 
19 
Xue et al., 1998, Hudson et al., 2001). These differing markers can help to distinguish 
between the basal and luminal cell types in prostate epithelium.  
Similar to basal cells, neuroendocrine cells are insensitive to androgen, but like luminal 
cells they are terminally differentiated (Table 1.2). There are very few within the 
epithelium, and their role is still largely unknown (Bonkhoff and Remberger, 1993). 
They secrete many different growth factors and hormones which help to stimulate 
proliferation and differentiation in the epithelium (Di Sant'Agnese, 1998, Li et al., 
2016). They can be identified by their markers; neuron-specific enolase (NSE) and 
chromogranin A (CGA) (Yao et al., 2011, Mjones et al., 2017) (Table 1.1). 
The stromal tissue contains extracellular matrix (ECM), blood vessels and a myriad of 
cell types, including fibroblasts, smooth muscle cells and immune cells (Livermore et 
al., 2016, Packer and Maitland, 2016). It is separated in normal prostate from the 
epithelium by the BM. A proportion of stromal cells express AR and are androgen-
sensitive. Stromal androgen signalling regulates the expression of growth factors, 
including keratinocyte growth factor, FGFs and insulin-like growth factor (IGF), which 
diffuse into the epithelium to promote growth and differentiation (Planz et al., 1998, 
Kwabi-Addo et al., 2004, Lai et al., 2012, Yu et al., 2012). Various studies also show that 
stromal AR plays a key role in the development and growth of BPH, primary prostate 
tumours and metastasis (Henshall et al., 2001, Lucia and Lambert, 2008, Lai et al., 
2012).  
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Figure 1.3: The human prostate epithelium forms a hierarchical pathway. (A) The majority 
of the epithelium consists of terminally differentiated luminal calls, followed by 
undifferentiated basal cells and a few neuroendocrine cells and stem cells. The epithelium sits 
on top of the basement membrane which is surrounded by the stroma. (B) Quiescent stem 
cells differentiate into rapidly dividing transit amplifying cells. Transit amplifying cells 
differentiate into committed basal cells which are on track to differentiate into the final cell 
type, secretory luminal cells (Adapted from Oldridge, Pellacani et al. 2012).  
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Table 1.1: Cell types found in prostate epithelia and their known expressed markers. 
Cell Type Marker Reference 
Luminal Cell 
PSA (Myers and Grizzle, 1996) 
PAP (Myers and Grizzle, 1996) 
CK18 (Sherwood et al., 1990) 
CK8 (Sherwood et al., 1990) 
NKX3.1 (He et al., 1997) 
AR (Prins et al., 1991) 
Committed Basal 
Cell 
CK5 (Sherwood et al., 1990) 
CK14 (Sherwood et al., 1990) 
p63 (Liu et al., 1997) 
Transit Amplifying 
Cell 
CD49bhigh (Guzman-Ramirez et al., 2009) 
CD133low (Grey et al., 2009) 
CK5 (Sherwood et al., 1990) 
CK14 (Sherwood et al., 1990) 
p63 (Liu et al., 1997) 
Neuroendocrine 
Cell 
CGA (Yao et al., 2011) 
NSE (Mjones et al., 2017) 
Synaptophysin (Wiedenmann et al., 1986) 
Stem Cell 
CD44high (Collins et al., 2005) 
CD133high (Collins et al., 2005) 
α2β1 integrinhigh (Collins et al., 2005) 
CD166 (Jiao et al., 2012) 
Sca-1 (Xin et al., 2005) 
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1.2 Prostate Cancer 
1.2.1 Premaligancies of prostate cancer  
Proliferative inflammatory atrophy (PIA) is an abnormality in the prostate that is 
thought to be a precursor to PCa. It occurs in the peripheral zone like PCa, and it 
involves the atrophy of prostate tissue as well as inflammation (Putzi and De Marzo, 
2000). The molecular signatures of prostate cancer start to appear at this stage, such 
as downregulation of tumour suppressors like NKX3.1, CDKN1B and PTEN (Figure 1.4) 
(Ruska et al., 1998). 
It is thought that PIA then goes on to develop into prostatic intraepithelial neoplasia 
(PIN) which also occurs in the peripheral zone of the prostate. Low-grade PIN consists 
of a few abnormal cells in the prostate, whereas high-grade PIN consists of 
hyperproliferative luminal cells, shortened telomeres, reactive stroma and a TMPRSS2-
ERG fusion, the most common genetic abnormality in PCa (Tomlins et al., 2005, Polson 
et al., 2013). Due to high-grade PIN cells having many similar characteristics to PCa 
cells, it implies that the development of prostate cancer is likely. When prostate cancer 
develops, not only is there hyperproliferation of luminal cells, but also the loss of the 
basal epithelial cells and BM (Barsky, 1983, Lang et al., 2000). Immune cells also start 
infiltrating the tumour, telomerase becomes activated and the tumour suppressor 
genes PTEN, RB1 and NKX3.1 are deleted (Figure 1.4) (Wymenga et al., 2000, 
Kunderfranco et al., 2010, Baca et al., 2013). Even though telomerase is active to 
extend the life span of cancerous cells, PCa cells have abnormally short telomeres in 
comparison to other cancers  (Sommerfeld et al., 1996). It has been suggested by von 
Zglinicki that high oxidative stress from cancer can result in telomeric DNA being 
poorly repaired as well as accelerating telomere loss (von Zglinicki, 2002).  
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Figure 1.4: The phenotypic and molecular changes that result in prostate cancer. Prostate 
cancer possibly develops from proliferative inflammatory atrophy (PIA) and prostatic 
intraepithelial neoplasia (PIN) via a series of molecular and phenotypic changes. Luminal 
secretory cells (orange cells) hyperproliferate resulting in PIN and cancer. Molecular changes 
include NKX3.1 and PTEN deletion and TMPRSS2-ERG fusion (Adapted from Packer and 
Maitland, 2016).  
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1.2.2 Epidemiology 
PCa is the most common cancer detected in males, and overall the second most 
common cancer in the UK. It is likely that 1 in 8 men will be diagnosed with prostate 
cancer, with more than half of those being diagnosed being aged 70 and over. In 
2015, there were 47,151 cases reported and 11,918 deaths. The number of deaths 
from PCa now surpasses breast cancer which makes it the third biggest killer in the 
UK after lung and bowel cancer (Cancer Research UK). 
1.2.3 Diagnosis 
Men over the age of 50 can be regularly screened for PCa via blood PSA testing. 
However, raised blood PSA is not mutually exclusive to PCa; it can increase due to old 
age, BPH, infection and prostatitis (Obort et al., 2013). Despite PSA being termed as a 
prostate-specific antigen, it can also be expressed in other tissues such as the ovary, 
salivary glands, lung and breast (Smith et al., 1995). PSA testing has been found to 
have a sensitivity of 86% and specificity of 33% when PSA levels were 4 ng/ml or 
below (Hoffman et al., 2002). Therefore, PSA testing can often result in false positives 
and hence results in treating patients unnecessarily.  
If high PSA levels are detected, the patient then undergoes multiple transrectal 
ultrasound (TRUS) biopsies and MRI scans. The presence and progression of PCa can 
then be defined by its tissue architecture via the Gleason grading system (Gleason, 
1966). Biopsies which are graded Gleason 3 to 5 are considered to be cancerous, with 
grade 5 having the least differentiated glands. It is likely that there will be multiple 
Gleason grades within the cancer biopsy, which results in the addition of Gleason 
grades, totalling up to Gleason grade 10. For example, Gleason grade 7 can be 
comprised of 3+4 tumours (with the majority being Gleason grade 3) or 4+3 tumours 
(with the majority being Gleason grade 4) (Chen and Zhou, 2016). The Gleason 
grading system helps determine the most successful treatment option and hence 
improves the patient’s prognosis. However, it only partially takes into account the 
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heterogeneous nature of PCa and the fact that it is a multifocal disease (Clark et al., 
2007). Therefore, a more specific PCa biomarker is required to avoid overtreatment 
and introduce a more personalised treatment regime for patients.  
1.2.4 Treatment of localised tumours 
Localised prostate tumours are often slow growing and have low chances of 
spreading. In these cases, active surveillance of PSA levels and regular biopsies is 
required, as treatment might not be necessary (Kollmeier and Zelefsky, 2012). This 
prevents overtreatment of these men, and improves their quality of life. However, it 
requires an accurate classification of the Gleason grade of the tumour (Gleason, 1966).  
If the tumour is localised but has a higher risk of metastasising, the patient has several 
options for treatment; a radical prostatectomy (RP), radiotherapy, or focal therapy. RP 
is a surgical treatment whereby the entire prostate is removed. This is a successful 
treatment option if the cancer is completely contained within the prostate. However, 
it comes with a host of side effects including incontinence and impotence. It is also 
only suitable if the patient has no other health problems.  
There are two forms of radiotherapy which are available to treat local and locally 
advanced PCa: external beam radiation therapy (EBRT) or directed brachytherapy. 
Both forms of radiotherapy kill cancer cells by stopping them from growing and 
spreading throughout the body. Often radiotherapy is paired with hormone therapy 
to shrink the tumour as much as possible, so it is easier to target. EBRT includes image-
guided intensity-modulated radiation therapy (IMRT) and 3D-dimensional conformal 
radiation therapy (3D-CRT) (Heidenreich et al., 2014). The advantage of IMRT over 3D-
CRT is that the intensity of the radiation beams can be controlled and therefore 
toxicity to surrounding tissues is reduced, while still maintaining a high dosage of 
radiation to the tumour (Bauman et al., 2012). Brachytherapy on the other hand is 
considerably more localised than EBRT due to using implanted radioactive seeds 
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directly into the prostate. This greatly minimises the amount of radiation to nearby 
healthy tissues (Koukourakis et al., 2009). 
Focal therapy is used as a form of treatment for patients’ whose tumour is restricted 
to one lobe. For high-intensity focused ultrasound (HIFU) a probe is inserted 
transrectally to kill cancer cells using high-frequency ultrasound. HIFU is a new 
treatment, and therefore the side effects and long-term success rates are still 
unknown. The advantages of the treatment include a short recovery time, no surgery 
and the ability to have HIFU again if the cancer regresses (Madersbacher et al., 1995). 
Photodynamic therapy (PDT) involves the intravenous delivery of photo-sensitive 
drugs which upon activation with light, cause cell death within prostate tissue 
(Koudinova et al., 2003). This is more sensitive than other focal therapies. However the 
photo-sensitive drugs stay in the patient’s bloodstream for weeks after which requires 
them to protect themselves from the sun (Moore et al., 2009). Cryotherapy destroys 
cells subjecting them to freezing and thawing cycles and extremely low temperatures 
(de la Taille et al., 2000). Argon gas or liquid nitrogen is administered to specific 
regions in the prostate under TRUS (Nomura and Mimata, 2012). Cryoablation can 
also be used as a salvage therapy after relapse, however it requires protection of 
surrounding tissues from the low temperatures (Cohen and Miller, 1994).  
1.2.5 Treatment of metastatic tumours 
Metastasis is classified as one of the hallmarks of cancer (Hanahan and Weinberg, 
2011). Up to 40% of men will develop metastatic PCa despite local treatment, and 
90% of these metastases will occur in the bone (Beltran et al., 2011). In order to invade 
the BM and stroma, primary tumour cells undergo epithelial-to-mesenchymal 
transition (EMT). This involves a switch from an epithelial to a mesenchymal 
phenotype, including a loss in cell polarity, cell adhesion and low levels of E-cadherin 
(Valastyan and Weinberg, 2011).  
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Metastatic and high-grade PCa are both treated with drugs which inhibit the growth 
of the tumour cells by depriving them of androgens. This form of treatment is referred 
to as androgen deprivation therapy (ADT), and there are four main categories:  
1. Anti-androgen therapy: AR is blocked to prevent the activation of androgen 
target genes, e.g. bicalutamide (Iversen et al., 2000)  
2. Gonadotropin-releasing hormone (GnRH) antagonist: blocks GnRH 
receptor to stop the production of testosterone, e.g. degarelix (Steinberg, 
2009) 
1. Luteinising hormone releasing hormone (LHRH) agonist: inhibition of LH 
resulting in the decrease in testosterone and DHT production, e.g leuprorelin 
acetate (Persad, 2002) 
2. Oestrogen treatment: inhibits 5- reductase to stop testosterone 
production, e.g. diethylstilbestrol (Clemons et al., 2013) 
1.2.6 Treatment of castrate resistant prostate cancer 
Patients which undergo ADT therapy for high grade prostate tumours initially show 
regression of the tumour, however they eventually become hormone resistant. The 
cancer is then referred to as castration-resistant prostate cancer (CRPC). The 
mechanisms by which CRPC arises are discussed in section 1.3.4. It is estimated that 
28% of PCa patients develop CRPC and these patients have a mean survival of 13.5 
months after CRPC diagnosis (Hirst et al., 2012). Therefore a major focus of current 
PCa research is the development of more successful next generation androgen 
deprivation therapies and CRPC chemotherapy agents. Current drugs that are able to 
prolong a patient’s survival but are not curative, include:  
1. Enzalutamide: 2nd generation antiandrogen which inhibits AR binding to DNA 
to activate AR target genes (Scher et al., 2012)  
28 
2. Apalutamide: 2nd generation antiandrogen which blocks translocation of AR 
to the nucleus via competitive binding to the ligand binding domain (Clegg et 
al., 2012)  
3. Cabazitaxel: 3rd generation taxane which has a lower affinity to p-
glycoprotein compared to other taxanes, and it also targets microtubules and 
AR trafficking (Paller and Antonarakis, 2011)  
4. Radium-223 dichloride: α-emitting radionuclide which targets bone 
metastases by mimicking calcium (Deshayes et al., 2017)  
5. Abiraterone acetate: an inhibitor of the enzyme CYP17A to prevent the 
synthesis of androgen from the adrenal glands and testes (De Bono et al., 
2011)  
6. Sipuleucel-T: immunotherapy treatment for early asymptomatic metastatic 
CRPC (Kantoff et al., 2010)  
7. Docetaxel: 2nd generation taxane which inhibits cell division and AR trafficking 
by targeting microtubules (James et al., 2015) 
1.2.7 Clonal evolution model  
The clonal evolution model (also known as the stochastic model) is the traditional 
view by which a tumour arises. It suggests that any cell has the potential to initiate a 
tumour when a mutation occurs in a tumour suppressor or oncogene. From here the 
founder cell will grow via mitosis to form a tumour. The tumour can then become 
heterogeneous via further mutations in the progeny of the founder cell (Nowell, 1976). 
Recently, it has been shown that a minimum of one to ten driver mutations is all that 
is required in a founder cell to result in cancer (Martincorena et al., 2017).  
1.2.8 Cancer stem cell model 
Adult SCs are present in the majority of human tissues where they aid regeneration, 
repair and tissue homeostasis. Unlike totipotent embryonic SCs, they are limited in 
their differentiation potential and are therefore referred to as being multipotent. Adult 
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SCs are largely quiescent cells, but they are triggered into division when damage 
occurs (Ojeh et al., 2015). This causes the SCs to give rise to their daughter TA cells, 
which subsequently commit to producing highly differentiated cells to replenish the 
cells after damage. 
The cancer stem cell (CSC) model suggests that a small population of cells within a 
tumour are able to initiate and maintain tumour growth, and hence without these 
cells the tumour would regress. Like adult SCs, they are multipotent and are able to 
undergo self-renewal. However, they have dysregulated differentiation and 
proliferation, allowing a heterogeneous population of cells to occur within the 
tumour. In this model, it is considered that the other cells in the bulk of the tumour 
are non-tumour initiating, which means that CSCs need to be targeted directly to 
prevent farther cancer growth and relapse (Archer et al., 2017, Batlle and Clevers, 
2017). The clonal evolution model and CSC model for tumour development may not 
be mutually exclusive but rather, in reality, tumours might form due to a combination 
of both. 
CSCs have been identified in many cancers such as: glioblastomas (Singh et al, 2003), 
acute myeloid leukemia (Bonnet and Dick, 1997), colon (Ricci-Vitiani et al., 2007), lung 
(Eramo et al., 2008), breast (Al-Hajj et al., 2004), bladder (Li et al., 2016) and pancreatic 
(Li et al., 2007, Frame et al., 2017, Frame et al., 2013) cancers. Isaacs and Coffey (1989) 
were the first to suggest that cancerous SCs could be present in PCa. Their model 
predicts that androgen-independent SCs are able to differentiate into androgen-
independent TA cells. The TA cells are androgen-responsive which allows them to give 
rise to androgen-dependent secretory luminal cells (Table 1.2). This model came 
about from a series of androgen cycling experiments in male rats; whereby after 
castration the prostate gland can be fully restored when androgen levels are replaced 
(Isaacs and Coffey, 1989).  
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Since then, CSCs have been successfully identified in PCa (Collins et al, 2005). They 
form a rare (0.1%) and treatment-resistant population within prostate tumours, which 
enables them to ‘hide’ within the bulk of the tumour away from chemotherapy and 
radiotherapy treatments (Packer & Maitland, 2016). This is due to CSCs not expressing 
AR and therefore they cannot be targeted by ADT (Table 1.2). Also, they undergo self-
renewal as well as differentiation into TA, and hence CB and luminal cells, to 
regenerate the tumour and cause a relapse. It has been discovered that CSCs are 
resistant to radiation and the chemotherapy drug, eptoposide (Frame et al., 2017, 
Frame et al., 2010). Therefore it is currently thought that to treat PCa, the CSCs 
themselves need to be directly targeted to prevent regrowth of the tumour (Maitland 
and Collins, 2008). The PCa CSCs can be selected using the putative markers: CD133, 
CD44 and α2β1 integrinhigh (Table 1.1) (Collins et al., 2005).  
1.2.8.1 Evidence luminal cells are the cell of origin 
The cell of origin in a tumour is the cell which has been targeted for mutation that 
results in the formation of a cancerous tumour. This could be the SCs themselves, but 
there also remains a debate over whether basal or luminal cells are the cell of origin 
in PCa.  
The majority of cells within a prostate tumour are thought to be luminal cells, due to 
the expression of luminal specific makers: CK8, CK18, AR, PSA and PAP (Table 1.1). 
Luminal progenitor cells have been found in prostate tumours within mice, however 
the mouse prostate is structurally different to the human prostate Liu et al. (2011), 
(Agarwal et al., 2015). Wang et al., has also identified a subpopulation of luminal cells 
in mice that are able to survive after androgen deprivation, called castration resistant 
NKX3.1 expressing cells (CARNs) (Wang et al., 2009). These cells are present in PIN 
and carcinoma lesions after a PTEN deletion, which suggests that they could be the 
origin of PCa (Wang et al., 2009). As of yet, a luminal CSC has not been successfully 
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isolated from primary human prostate tumours, and therefore it cannot be confirmed 
whether luminal cells are the source for PCa.  
1.2.8.2 Evidence Basal Cells are the Cell of Origin 
There is a large amount of evidence to suggest that CSCs originating from basal cells 
could give rise to PCa. A small population of basal cells has been found to express 
known SC markers, CD133 and α2β1
high. This population also demonstrates known SC 
attributes: high proliferative potential in vitro and the ability to reform prostate-like 
acini in vivo (Richardson et al., 2004). This population of CD133+/α2β1high cells also 
shows cancer cell characteristics, and is able to differentiate into AR+ luminal cells, 
similar to the formation of primary prostate tumours (Collins et al., 2005).  The RNA 
signature of basal CSC population has been associated with a more aggressive type 
of prostate cancer (Smith et al., 2015). Finally, Goldstein et al., discovered that 
potentially basal cells could form a luminal phenotype tumour within 
NOD/SCID/IL2Rγnull mice after ERG, AKT and AR expression (Goldstein et al., 2010). 
1.3 Androgen Receptor  
1.3.1 Gene structure 
Androgens are a group of steroid hormones which are major regulators in the 
differentiation and development of the prostate epithelium (Oldridge et al., 2012).  AR 
is a nuclear receptor in the subfamily 3, group C, member 4 and is located on Xq12 
and it contains 8 exons, spanning approximately 180 kb (Hu et al., 2017). AR is found 
to be expressed all over the body and not just in the prostate. For example, expression 
is seen in the bone marrow, spleen, thymus and the brain (Dart et al., 2013). Androgen 
has a repressive effect on AR mRNA indicating that AR has a self-limiting expression 
(Olsen et al., 2016). This ensures a context dependent expression of AR and hence 
androgen regulated genes.  
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AR is a large 110 kDa protein, and is organised into four sections: The N-terminal 
transcriptional activation domain (NTD), DNA binding domain (DBD) with two zinc 
finger motifs, a hinge region and ligand-binding domain (LBD) (Hu et al., 2017, Berry 
et al., 2008). NTD is encoded by exon 1 and it helps regulate the transcription of AR 
(Hu et al., 2017). DBD determines how AR binds to the androgen response element 
(ARE) in the DNA promoter regions, and it is encoded in exons 2 and 3. The hinge 
region regulates the dimerization of AR when it moves into the nucleus. LBD binds to 
an androgen ligand in the cell cytoplasm, which results in specific downstream effects 
within the target cell. Exons 4-8 encode for both the LBD and hinge region (Livermore 
et al., 2016, Hu et al., 2017). Despite the presence of the LBD, AR can be activated 
without a ligand. This occurs via the hormone-independent activation function (AF1) 
within the NTD and it allows CRPC to develop. The hormone-dependent activation 
function 2 (AF2) is located within the LBD and does require a ligand (Figure 1.5) 
(Livermore et al., 2016).  
At the end of exon 1 there is a series of CAG repeats. The length of the repeat 
sequence is inversely correlated with the transcription promoting activity of AR; hence 
the longer the polymorphism repeat the less AR activity. CAG repeat length has been 
shown to vary in different ethnic populations. For example, those of Afro-Caribbean 
lineage have the shortest mean repeat length (19.6 ± 3.2) and those of Thai lineage 
have the longest mean repeat length (23.1 ± 3.3) (Ackerman et al., 2012). The research 
around whether the repeat length has an association with the risk of prostate cancer 
has been controversial up until recently. A meta-analysis shows that short 
polymorphic CAG repeats may increase the susceptibility of developing PCa (Qin et 
al., 2017). 
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Table 1.2: A list of prostate epithelial cells and their respective AR expression and 
responsiveness to androgen (Adapted from Oldridge et al, 2012). 
Cell Type AR Expression Androgen responsiveness 
Stem Cells AR- Non-responsive 
Transit Amplifying Cells AR- Responsive 
Committed Basal Cells AR- Responsive 
Luminal Cells AR+ Dependent 
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Figure 1.5: The AR gene and protein structure. The locus is located at Xq11-12 and it 
contains eight exons. These exons encode a protein with four domains: the N-terminal 
transcription activation domain (NTD), the C-terminal ligand binding domain (LBD), the central 
DNA binding domain (DBD) and the hinge region. AR can be activated without a ligand via 
AF1 domain. It can also be activated with a ligand via AF2 domain.  
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1.3.2 Genomic and non-genomic signalling pathways 
The genomic signalling pathway is the common way by which AR transduces a signal 
when androgens bind to AR. Firstly, the androgen testosterone moves into the cell 
where it is converted into DHT by 5-reductase at the plasma membrane. DHT binds 
to the LBD of AR and induces a conformational change, causing AR to dissociate from 
heat shock proteins (Hsp) and chaperones within the cytoplasm. From here AR is 
phosphorylated, enabling its translocation to the nucleus. Once it reaches the nucleus, 
it dimerizes with another activated AR and binds to a series of coactivators (Livermore 
et al., 2016). The dimerized AR binds to ARE in the promoter regions of the androgen 
target genes, including those linked with prostate disease (Berry et al., 2008) (Figure 
1.6A). This activates multiple genes and promotes functions such as cell survival and 
proliferation (Livermore et al., 2016). For example, the PSA gene contains three AREs 
which demonstrates that luminal cells are responsive to androgen signalling (Berry et 
al., 2008). 
Unlike the genomic signalling pathway that takes several hours to complete, the non-
genomic signalling pathway can occur within minutes. This non-genomic signalling 
pathway does not require AR to translocate into the nucleus and bind to DNA. Instead, 
activated AR binds to a series of intracellular signalling molecules such as PI3K, Src 
and Ras/Raf-1. This then triggers the activation of the MAPK/ERK pathway which 
induces cell proliferation (Livermore et al., 2016) (Figure 1.6B). This pathway does not 
occur in non-cancerous luminal cells since they are terminally differentiated, so that 
they are no longer able to proliferate.  
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Figure 1.6: AR signalling via the genomic and non-genomic pathways.  (A) Testosterone 
is converted to DHT that binds to AR in the cytoplasm. AR moves into the nucleus and 
dimerizes on an ARE in DNA, upstream from androgen regulated genes. (B) AR is activated 
without the presence of androgens and it does not translocate into the nucleus. Target genes 
are activated via the MAPK/ERK pathway that can be initiated by signalling molecules (PI3K, 
Src, Ras/Raf1) binding to phosphorylated AR.  
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1.3.3 The role of AR in PCa  
It has been known that PCa is an androgen-sensitive disease since 1941 from the 
research of Huggins and Hodges (Huggins, 1941). ADT targets the androgen-
responsive luminal cells within the tumour to stop growth (Table 1.2). However, the 
inevitable development of CRPC, has increased the demand for novel therapeutics 
(see section 1.2.6) (Karantanos et al., 2013). Therefore, continued understanding and 
investigation of the role of AR in prostate cancer should help elucidate possible ways 
to tackle CRPC. 
1.3.4 Adaptations of AR signalling in CRPC 
Even though androgen levels are low in patients undergoing ADT, AR signalling is still 
able to be reactivated resulting in CRPC. There are various pathways by which AR can 
adapt to ADT, such as forming splice variants, amplifying expression and inactivation 
of corepressors of AR signalling pathways.  
Forming many mRNA isoforms via splicing allows a range of proteins, encoded by the 
same gene, to have different roles within the cell. Aberrant AR mRNA splicing has 
been linked to the onset of different types of cancer and specifically PCa (Pal et al., 
2012). There are many different AR splice variants, but the most prevalent are the 
isoforms AR-V7 and Arv567es, which lack the LBD but are still able to localise to the 
nucleus when there are no androgens present (Hu et al., 2009, Sun et al., 2010). PCa 
patients that express these splice variants have poor prognoses (Hornberg et al., 
2011).  In particular, AR-V7 has been used as a biomarker for resistant prostate cancer 
as it has been found in circulating tumour cells of CRPC patients (Steinestel et al., 
2015).   
Mutations in AR have been found in 10-30% of CRPC patients (Wallen et al., 1999). 
The majority of these mutations occur in the LBD, but many also occur in the NTD 
(Gottlieb et al., 2012). The most common mutation in CRPC patients is the point 
mutation T877A which can be used as another biomarker for CRPC. The substitution 
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of a threonine for an alanine at position 877 in the LBD results in a decrease in AR 
specificity to DHT. The mutation increases the space in the binding pocket, allowing 
for other hormones such as oestrogen and progesterone to enter (Risstalpers et al., 
1993, Gaddipati et al., 1994).  
AR expression is increased in CRPC patients, which allows the tumour cells to be 
hypersensitive to the low levels of testosterone. AR copy number has been found to 
be highly elevated in 30% of CRPC patients, resulting in more protein being expressed 
(Visakorpi et al., 1995).  
AR signalling occurs via the non-genomic pathway when androgens are not present. 
Src expression has been shown to be upregulated in CRPC cells to increase AR 
signalling (Asim et al., 2011). Src inactivates corepressors which bind to transcription 
factors or AR itself, thereby restricting the transcriptional activation of AR under 
normal circumstances. In particular, the activity of the corepressor LCoR is suppressed 
by Src kinase which is an important step in the development of PCa carcinogenesis in 
vivo (Asim et al., 2011). 
1.3.5 The role of AR in differentiation 
AR has been found to be essential for differentiation of basal cells to terminally 
differentiated luminal cells in a range of studies (Berthon et al., 1997, Lee et al., 2012, 
Ling et al., 2001, Niu et al., 2008, Whitacre et al., 2002, Wu et al., 2007). AR also plays 
a role in proliferation of the epithelium, however there are conflicting studies as to 
whether it promotes or inhibits proliferation (Berthon et al., 1997, Simanainen et al., 
2007). 
The role of AR during differentiation of the prostate epithelia has been investigated 
using both mouse knock-out (KO) models and cell line models. Mouse models show 
that when AR is not present, luminal differentiation cannot reach completion. Firstly, 
Wu et al., showed that in mice that lack AR in the mature prostate (KO of exon 2 which 
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codes for the DBD) do not form the glandular infoldings and the luminal cells are a 
lot shorter than in the WT mice. However, it must be noted that luminal cells are still 
present and the gross structure of the prostate remaining intact, which suggests that 
differentiation is still able to occur despite AR not being expressed (Wu et al., 2007). 
Similarly, Simanainen et al., also generated a mouse KO model with an edit to the DBD 
which showed similar effects to Wu et al., whereby the prostate development was 
hindered (Simanainen et al., 2007). Lee et al. has also used a mouse KO model, as well 
as cell lines, to look specifically at the role of AR in basal cells. They found that 
increasing levels of AR in basal cells drives differentiation into luminal cells (Lee et al., 
2012). 
The majority of research has been done using mouse KO models, and this poses many 
limitations due to the differences in mouse and human prostate epithelial structure. 
Whitacre et al., used the rat prostate cell line CA25 transfected with AR, instead of a 
mouse model, to show that the addition of DHT results in the formation of luminal-
like columnar epithelial cells (Whitacre et al., 2002). They also found an increase in the 
expression of 6 integrin which is a marker for terminal differentiation in mouse 
keratinocytes. Whitacre et al. took this as another piece of evidence that 
differentiation was occurring with AR present. However, 6 integrin is a differentiation 
marker in a different cell type and animal, so it might not symbolise differentiation in 
the rat prostate. Also, it needs to be considered that the rat prostate is still different 
to the human prostate and so has not brought research closer to elucidating the role 
of AR in the human prostate.  
Recent research published during the course of this project showed that potentially 
AR is not required for luminal differentiation (Chua et al., 2018). CARNs are a rare 
population of luminal progenitor cells that are found in androgen deprived mice. Mice 
carrying a conditional allele of AR with an inducible NKX3.1 CreERT2 (cre recombinase) 
drive were used to demonstrate that in the absence of AR luminal markers, CK18 and 
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CK8 were still expressed and basal markers CK5 and p63 were not expressed. These 
results contradict the current research in mice models, however this could be due to 
the use of targeting rare CARN cells. 
To assess the role of AR in the human prostate, research by Berger et al. used newly 
immortalised primary human prostate epithelial cells and tumourigenic prostate 
epithelial cells. Expression of AR in these human cells resulted in a decrease in p63 
expression, a marker for basal cells, as well as small increase in the secretion of PSA, 
a marker for luminal cells. This hints at the possibility of AR being involved in luminal 
differentiation, but Berger et al. noted that not all the luminal cell markers are 
expressed (Berger et al., 2004). Therefore, the role of AR during differentiation of 
luminal cells in the human prostate is yet to be elucidated  
Furthermore, it is unknown to what extent AR determines luminal differentiation and 
whether other factors are involved. It is known that retinoic acid (RA) and androgens 
work together to initiate bud development in the embryo urogenital sinus to form the 
prostate (Bryant et al., 2014). However, using androgen-dependent and independent 
cell lines, it has been shown that both RA receptor (RAR) and AR are also required for 
luminal differentiation in the adult prostate (Rivera-Gonzalez et al., 2012, Rane et al., 
2014). This is the first evidence of AR playing a minor role in the regulation of prostate 
specific genes and that RA is also required for development in the mature prostate 
(Rivera-Gonzalez et al., 2012). Therefore, perhaps RA receptors could also be involved 
in the differentiation of the prostate epithelium alongside AR.  
1.4 Genetic Engineering Technologies Using Programmable 
Nucleases 
The development of programmable nucleases has allowed genome editing to 
become a powerful tool in research, biotechnology and medicine. Over the last three 
decades, a range of technologies has been developed: zinc finger nucleases (ZFNs), 
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transcription-activator-like effector nucleases (TALENs) and clustered regularly 
interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) (Table 1.3).  
Modern genetic engineering technologies involve directing a DNA nuclease using 
protein or RNA that are designed to recognise specific nucleotide sequences. The 
nucleases then cleave the DNA to form a double stranded break (DSB). The cell 
recognises that there is a break in the DNA and it induces two repair mechanisms; 
non-homologous end joining (NHEJ) and homology-directed repair (HDR). The NHEJ 
pathway is preferred when a gene KO is required, as it results in small insertions, 
deletions and possibly a frame shift, causing the gene to no longer function. If two 
DSBs are created, they will be repaired by NHEJ by removing the DNA flanked by the 
DSBs. On the other hand, HDR can occur which can be used to insert point mutations 
or a sequence of DNA. This requires an exogenous donor DNA template, which are 
either single stranded oligodeoxynucleotides for small insertions or plasmids for a 
large gene insertion (Hendriks et al., 2016) (Figure 1.8).  
Table 1.3: Comparison of different genetic engineering technologies using 
programmable nucleases (Adapted from Kim and Kim, 2014) 
 TALENs ZFNs CRISPR/Cas9 
Target DNA recognition Protein-DNA Protein-DNA RNA-DNA 
Components 
TALE-FokI 
fusion protein 
ZF-FokI fusion 
protein 
gRNA and Cas9 
Success rate Low High High 
Off-target efficiency  Low High Low 
Time consumption Long Long Short 
Cost  High High Low  
1.4.1 ZFNs  
ZFNs were developed in 1994 and were the first genetic engineering technology 
which utilised the fusion of a DNA nuclease (FokI) with DNA binding proteins (zinc 
finger proteins) (Choo and Klug, 1994). Zinc finger (ZFs) proteins are each formed of 
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a single atom of zinc bound to approximately 30 amino acids (Pavletich and Pabo, 
1991). The ZFs are bound to FokI via a short linker, and a spacer of five to six bp is 
required between the binding sites for FokI (Fig 1.7A) (Bibikova et al., 2001). In order 
for FokI to cleave DNA it must dimerise. Therefore, a pair of ZFNs is required to target 
a specific DNA site, which greatly increases the specificity of ZFNs. In each ZFN there 
is usually three to six zinc finger repeats which are able to recognise between nine to 
18 bp on the target DNA. Each repeat recognises three nucleotides which greatly 
reduces the target range of ZFNs (Carroll, 2011).  
1.4.2 TALENs 
TALENs replaced ZFNs in 2009 (Boch et al., 2009). They are similar to ZFNs due to the 
use of FokI fused with customisable DNA binding proteins. In the case of TALENs the 
DNA binding domain is composed of repeats derived from transcription-activator-
like effectors (TALEs). TALEs are proteins secreted by Xanthomonas bacteria via their 
type III secretion system to alter the transcription of the host plant they are invading 
(Boch and Bonas, 2010). The DNA binding domain of TALEs contain 33-34 highly 
conserved amino acids, each of which recognises a single nucleotide (Figure 1.7B). 
The 12th and 13th amino acids are referred to as the repeat variable diresidue (RVD) 
(Moscou and Bogdanove, 2009). The variation of amino acids at these positions allows 
for greater target DNA specificity. ZFNs and TALENs have similar efficiencies when 
targeting a specific DNA sequence. However, TALENs are easier to design and have a 
higher rate of cleavage activity (Kim and Kim, 2014).  
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Figure 1.7: ZFN and TALEN programmable nucleases. (A) ZFNs are formed of two FoxI 
nucleases connected to zinc finger proteins via a linker. Each zinc finger repeat recognises a 
nucleotide triplet. (B) TALENs are formed of two FoxI nucleases connected to transcription-like 
effectors. Each transcription-like effector recognises a single nucleotide via the repeat variable 
diresidue (Adapted from Kim and Kim, 2014)   
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1.4.3 CRISPR/Cas9 
The CRISPR/Cas9 genetic engineering system has recently become a popular method 
for modifying specific sites within a gene in a variety of organisms. It is a more 
efficient, reliable and rapid way of editing genes than ZFNs and TALENs.  
CRISPR/Cas9 is derived from a bacterial adaptive immunity system, which was first 
found in Streptococcus pyogenes. The CRISPR locus contains repetitive elements 
(repeats) that are interspaced with incorporated invading DNA sequences 
(protospacers). This is used as a ‘memory’ store of previous infections so if the 
bacterium is re-infected it can fight the invader. When a reinfection occurs, the CRISPR 
repeat arrays are transcribed into crRNAs (CRISPR RNA). Each crRNA contains a part 
of the CRIPSR repeat and a protospacer. The crRNAs then hybridizes with tracrRNA 
(trans-activating RNA) to form a complex with the nuclease Cas9 (crRNA-
trancrRNA:Cas9). This complex is guided by the protospacers that recognise 
protospacer adjacent motifs (PAMs) and the complementary protospacers within the 
invading DNA. PAMs are found at the 3’ end of the protospacer in the invader DNA, 
but not in the bacterial DNA CRISPR region. This allows the bacteria to distinguish 
itself from the invader (Mali et al., 2013). Cas9 nuclease is led towards the invading 
DNA where it can then cleave the DNA to form a DSB to stop an infection from 
occurring (Sander and Joung, 2014). 
This CRISPR/Cas9 system from S. pyogenes has been adapted to be able to create 
specific DSB breaks to allow genes to be edited, knocked-out or introduced within 
the laboratory. An engineered guide RNA (gRNA) contains crRNA and tracrRNA like 
sequences (Figure 1.8). It contains a designed 20 bp sequence (like the protospacer 
in bacterial CRISPR) that targets a sequence flanked by a PAM in the target genome. 
It also contains a sequence which helps scaffold the gRNA to the Cas9 (Hille and 
Charpentier, 2016).  
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Figure 1.8: CRISPR-Cas9 genetic editing system. The nuclease Cas9 is directed to a specific 
site within the DNA via a designed gRNA. From here a DSB is formed which is then repaired 
by the cell via NHEJ or HDR. This results in either indel changes in the DNA causing a gene KO 
or inserting donor DNA into the host DNA. 
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1.4.3.1 Applications of CRISPR/Cas9 
CRISPR/Cas9 is an incredibly diverse system which not only can be used for gene 
editing but also for epigenetic modifications, transcriptional control, generating 
animal models and allowing high throughput genetic screens.  
The most simple and effective use for CRISPR/Cas9 is to generate a gene KO that has 
been previously described. But guiding donor DNA to a desired location within the 
genome can also use it to create a gene knock-in. CRISPR/Cas9 can also create specific 
single nucleotide edits.  
Editing the epigenome allows changes to gene expression without permanent 
changes to the DNA sequence. CRISPR/Cas9 has been adapted to edit both DNA 
methylation and histone modifications. This occurs by fusing Cas9 with 
methyltransferases (e.g DNMT3A) (Anton and Bultmann, 2017), acetyltransferases (e.g 
p300) (Hilton et al., 2015) or histone demethylases (e.g LSD1) (Kearns et al., 2015). 
The CRISPR/Cas9 system has been adapted to create two modified systems called 
CRISPRi and CRISPRa which are both able to activate or repress genes without editing 
their epigenetics. Both systems use an inactive form of Cas9, referred to as “dead” 
Cas9 (dCas9) (Bikard et al., 2013). dCas9 has no catalytic function but is still able to 
bind to specific DNA sequences. From here it can block RNA polymerase but also 
induce the formation of heterochromatin to cause gene silencing. This method of 
gene regulation is referred to as CRISPRi (Qi et al., 2013). CRISPRa on the other hand 
involves dCas9 fusing to the transcriptional activation domain Vp64 to induce gene 
expression (Maeder et al., 2013).  
Similar to the use of RNAi, CRISPR/Cas9 can be used to screen for modifications in 
whole genomes within a single experiment. Cas9 and gRNA libraries can be 
introduced into cells to generate a range of knock-outs and the phenotypes of 
interest can be screened. In cancer research, this allows the identification of novel 
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genes involved in cancer development (Chen et al., 2015, Shi et al., 2015) and drug 
resistance (Wang et al., 2014).   
CRISPR/Cas9 is therefore a very powerful tool that has many applications within 
genetic and molecular biology. However, the extent of the off-target effects is still 
unclear. A recent study has demonstrated that off-target effects caused by 
CRISPR/Cas9 can result in large chromosomal rearrangements (Kosicki et al., 2018).  
1.5 Models Used to Study Prostate Cancer  
1.5.1 Culture of cell lines in 2D 
There are a number of immortalised prostate specific cell lines that allow the study of 
PCa biology and progression (Table 1.4). Cell lines are a good model of study due to 
their ease and indefinite culture in 2D. They are also easy to transfect and manipulate, 
which makes them a suitable candidate for genetic editing. However, many cell lines 
have been around for decades and therefore no longer represent the patient from 
which they were harvested (Izadpanah et al., 2008, Kawai et al., 1994, Meissner et al., 
2008) (Figure 1.9). This is due to the accumulation of genetic and epigenetic 
mutations. Therefore, cell lines are a useful model to study for initial research, but to 
replicate the changes that occur within a patient other models need to be used.  
BPH is a chronic disease that occurs later in a man’s life and involves the 
hyperproliferation of prostate cells in the transition zone. It results in the constriction 
of the descending urethra causing urinary tract infections and discomfort (Briganti et 
al, 2009). Unlike PCa, BPH involves the proliferation of basal cells instead of luminal 
cells (Dermer, 1978). The BPH-1 cell line is an epithelial cell line derived from the 
prostate of a 68-yr-old man undergoing transurethral resection of the prostate (TRUP) 
due to urinary constriction caused by BPH. When cultured in RPMI +5% FCS medium, 
they remain undifferentiated and do not express AR (Hayward et al, 1995). However, 
when they are triggered to differentiate into luminal cells, they start to express AR 
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(Pellacani et al., 2014). The BPH-1 cell line has been previously transduced with a 
lentiviral vector in the Maitland lab by Frame and Pellacani (Frame et al., 2010). The 
lentiviral vector contains mOrange which is regulated by the luminal prostate specific 
PSA-probasin promoter. The mOrange can be visualised when the cells differentiate 
into luminal cells, and in particular when the BPH-1 cells are grown in 3D into 
spheroids (Pellacani et al., 2014). Non-tumourigenic BPH-1 cells can also initiate 
tumour growth when recombined with carcinoma associated fibroblasts (CAFs) or 
being exposed to carcinogenic levels of testosterone and estradiol (Hayward et al., 
1995). Therefore, for these reasons BPH-1 cells were chosen as a model for basal 
prostate differentiation.  
P4E6 cells were derived in our lab as a model for early, non-metastatic prostate cancer 
(Maitland et al., 2001). They express luminal and basal markers such as CK5, CK14 and 
PSA, but do not express AR when undifferentiated (Lang et al., 2006). This model was 
chosen to investigate the role of AR during the early development of cancer. 
Therefore, combined with BPH-1 cells as a model, the importance of AR in the 
differentiation of basal cells can be investigated in both cancerous and non-cancerous 
cells.  
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Table 1. 4: Comparison of available prostate cell lines (Adapted from Oldridge et al., 2012).  
Cell 
Line 
Origin 
Immortalisation 
method 
Reference 
Increasing 
Malignancy 
PNT1a 
Normal prostate cells from 
young male donors 
Transfection 
with the SV40 
large T antigen 
(Berthon et al, 
1995) 
 
PNT2-
C2 
BPH-1 
Epithelial cells from 68-yr-
old man with benign 
hyperplasia 
Transfection 
with the SV40 
large T antigen 
(Hayward et 
al, 1995) 
P4E6 
Well differentiated early 
Gleason 4 cancer 
Transfection 
with the human 
papillomavirus-
16 E6 gene 
(Maitland et 
al, 2001) 
RC165 
Benign tissue collected 
from African-American PC 
cancer patient 
Telomerase 
(Miki et al, 
2007) 
Bob TURP of CRPC tissue Spontaneous 
(Attard et al, 
2009) 
Serbob TURP of CRPC tissue Spontaneous 
(Attard et al, 
2009) 
PC346C 
Non-metastatic advanced 
prostate adenocarcinoma 
Transfection 
with a retrovirus 
(Marques et 
al, 2006) 
LNCaP 
Metastatic PC cells 
harvested from the left 
supraclavicular lymph 
node 
Spontaneous 
(Horoszewicz 
et al, 1983) 
VCaP 
Metastatic PC cells 
harvested from the 
vertebrae. 
Spontaneous 
(Korenchuk et 
al, 2001) 
DU145 
Metastatic PC cells from 
the brain 
Spontaneous 
(Stone et al, 
1978) 
PC3 
Grade 4 metastatic PC 
cells harvested from the 
bone 
Spontaneous 
(Kaighn et al, 
1979) 
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1.5.2 Culture of cell lines in 3D 
Recently, the ability to culture cells into 3D spheroids has led to a greater 
understanding of what occurs in vivo without the use of mouse models (Figure 1.9). 
Unlike normal 2D culture of cell lines, growing cell lines into spheroids in ECM 
(MatrigelTM Corning) surrounded by stroma, mimics the microenvironment that basal 
and luminal cells develop within the prostate. This promotes basal cell differentiation, 
and results in a hollow sphere that mimics an acinus, with a luminal and basal 
epithelial bilayer surrounding a lumen. This architecture is similar to what is seen in 
human prostate glands, thereby making spheroids a suitable model for prostate 
differentiation (Lang et al., 2006, Lang et al., 2001, Lang et al., 2000, Pellacani et al., 
2014). 
1.5.3 Culture of patient primary cells  
Culture of primary cells harvested from patient biopsies allows an invaluable insight 
into the heterogeneity of PCa and the variation between different patients (Figure 
1.9). The primary cell cultures are not immortalised, which avoids any genetic changes 
that occur during the immortalisation process, but subsequently this means that the 
cells can only be cultured for a limited time. Patient primary cells are also difficult and 
expensive to keep in culture.  
1.5.4 Mouse models  
The mouse model is used for the majority of in vivo research into PCa. Cell lines and 
primary tissue can be transplanted into immunocompromised mice (NOD/SCID or 
RAG-/- IL2C-/- mice) to form xenografts (Figure 1.9). This has shed light into the 
molecular mechanisms of how PCa develops. However, the mouse prostate is 
significantly divergent from the human prostate. Firstly, mouse prostates tend to 
atrophy instead of developing cancer or benign hyperplasia. Due to mice having a 
shorter life span, they are unable to accumulate the same level of mutations than a 
human would over many years (Sharma and Schreiber-Agus, 1999). The gross 
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structure of the prostate varies between humans and mice; mice have three lobes to 
the prostate whereas humans are alobular. Also, humans have a double layer of 
epithelial cells whereas the murine prostate only has a single layer (Maitland, 2013). 
Therefore, results derived from mouse models need to be treated with caution.  
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Figure 1.9: A comparison of different prostate cancer models. Every model has different 
advantages and disadvantages. Obtained with permission from Fiona Frame.  
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1.6 Research Aims 
There is conflicting evidence as to whether AR is essential for luminal differentiation. 
Therefore the aim of this was project to investigate whether AR is required for 
differentiation of basal to luminal secretory cells, and if so to what extent it is required.  
Hypothesis: Deletion of the AR gene via the CRISPR/Cas9 system still allows the 
differentiation of a normal luminal phenotype in prostate cancer.  
 To investigate this hypothesis, I have two clear aims: 
1. To KO all of the copies of the AR gene in basal BPH-1 and P4E6 cells using 
CRISPR/Cas9 system 
2. To investigate the role AR plays in normal basal to luminal differentiation in 
order to further understand differentiation of epithelial cells during the 
development of prostate cancer. 
Strategy: Once AR was successfully knocked-out in both the basal cell line models, 
differentiation was induced by growing the cells into 3D spheroids. From here it was 
investigated whether the cells are able to form spheroids, and if so, to what extent 
differentiation had occurred. This was then tested by staining for well-known 
differentiation markers. 
Possible outcomes: If AR is essential for differentiation the ARKO spheroids will not 
successfully form. However, if spheroids do form they will lack a structure consisting 
of basal and luminal layers. The ARKO clones will also remain basal, indicated by 
markers such as p63 and CK5. On the other hand, if AR is not essential for 
differentiation it could still occur. This might be due to other receptors taking over 
such as RAR, which has been shown to work alongside AR in prostate development. 
This will be detected by the presence of luminal markers (CK18, NKX3.1, PSA) in ARKO 
spheroids.   
54 
2. Materials and Methods 
2. 1 Mammalian cell culture 
2.1.1 Cell culture of cell lines 
All cell lines used in experiments were purchased from the American Type Culture 
Collection (ATCC, USA) except for the P4E6 cell line which was derived in our 
laboratory (Maitland et al., 2001) (Table 2.1). BPH-1 cells were gifted from Simon 
Hayward and BPH-1 PSA-Probasin mOrange (BPH-1 PPmO) cells were generated in 
our laboratory (Frame et al., 2010). BPH-1 and BPH-1 PPmO cells were cultured in 
Roswell Park Memorial Institute-1640 (RPMI, Gibco) supplemented with 5% foetal calf 
serum (FCS, Gibco) and 2 mM L-Glutamine (Invitrogen) (Table 2.1). LNCaP cells were 
cultured in RPMI with 10% FCS (Table 2.1). VCaP cells were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM, Gibco) supplemented with 10% FCS and 2 mM L-
Glutamine. P4E6 cells were cultured in Keratinocyte Serum-Free Medium (KSFM, 
Gibco) supplemented with 2% FCS, 50 µg/ml bovine pituitary extract (Invitrogen), 5 
ng/ml Epidermal Growth Factor (EGF, Invitrogen) and 2 mM L-Glutamine. All cell lines 
were cultured in T25, T75 and 10 cm dishes (Sarstedt or Corning) in sterile conditions 
at 37 °C in 5% CO2. 
2.1.2 Live cell counting using a haemocytometer  
Trypan Blue exclusion was used to count the number of viable cells. Briefly, cells grown 
as a monolayer were trypsinized and 0.4% Trypan Blue Stain (Sigma-Aldrich) was 
added to a cell suspension at a 1:1 ratio. The number of unstained cells was counted 
using a haemocytometer (Neubauer) as they were equivalent to live cell number. 
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Table 2.1: A summary of the human prostate cell lines used. 
Cell line Description Growth medium Reference 
BPH-1 
Human prostate epithelial cells 
derived from a 68 year-old man 
with benign hyperplasia and 
immortalised with SV-40. 
RPMI + 5% FCS 
(R5) 
(Hayward et 
al., 1995) 
BPH-1 
PPmO 
BPH-1 cells with a reporter gene 
inserted (PSA-Probasin 
mOrange) which fluoresce when 
AR is expressed upon 
differentiation. 
RPMI + 5% FCS 
(R5) 
(Frame et al., 
2010) 
VCaP 
Metastatic prostate cancer cells 
harvested from the vertebrae. 
DMEM + 10% 
FCS (D10) 
(Korenchuk 
et al., 2001)  
P4E6 
Human prostate epithelial cells 
derived from a well 
differentiated early stage cancer 
and immortalised with HPV16 E6 
retrovirus. 
KSFM + 2% FCS 
(K2) 
(Maitland et 
al., 2001)  
LNCaP 
Metastatic prostate cancer cells 
harvested from the left 
supraclavicular lymph node. 
RPMI + 10% FCS 
(R10) 
(Horoszewicz 
et al., 1983)  
2.1.3 Cryopreservation of cell cultures  
Cultured cells were harvested via trypsinisation and centrifuged at 1200 RPM for 3 
min. They were resuspended in freezing medium (10% (v/v) dimethyl sulfoxide (DMS), 
20% (v/v) FCS in RPMI) at a concentration of 1-2x106 cells/ml and transferred into 2 
ml cryovials (Greiner Bio-One). Before transferring to liquid nitrogen for long term 
storage, they were stored at -80 °C for 24 hr. 
2.2 Generation and Identification of AR Knock-Out Clones  
2.2.1 Minimal lethal dose of puromycin 
BPH-1 and P4E6 cells were seeded onto a 6-well plate at a density of 200,000 cells per 
well. The cells were grown until they were 70-80% confluent. Spent media was 
aspirated and the cells were washed with PBS. 2 ml of media containing increasing 
concentrations of the antibiotic puromycin dihydrochloride (0.25 µg/ml, 0.5 µg/ml, 
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1.0 µg/ml, 1.5 µg/ml, 2.0 µg/ml) (Sigma-Aldrich) was then added. The puromycin-
containing media was changed every two days for a week, after which the cells were 
then stained with 1% crystal violet (Sigma-Aldrich) and imaged.  
2.2.2 CRISPR/Cas9 transduction 
The CRISPR/Cas9 lentivirus was designed by Sigma-Aldrich to target exon 1 of the AR 
gene. Before lentiviral infection, 200,000 cells were seeded per well on a 6-well plate. 
They were infected with the AR targeting lentivirus for 12 hr at a 2:1 and 1:1 ratio 
(lentivirus:cell) as calculated from the transfection units per ml value provided. 
Controls used included an EMX1 targeting lentivirus (positive control) and a non-
targeting lentivirus (negative control) (Sigma-Aldrich). EMX1 is a gene involved in 
brain development and therefore it should not have any effect on the biology of 
prostate cells when it is knocked out (Chan et al, 2001). The transfected cells were 
then selected using 1.0 µg/ml puromycin in BPH-1 and BPH-1 PPmO cells and 2.0 
µg/ml puromycin in P4E6 cells. The transduced cells were grown in puromycin for 1-
2 weeks until they reached 80% confluency.   
2.2.3 Ring cloning 
To generate individual colonies, 1000 cells were seeded onto a 10 cm dish and grown 
further. A sterile cloning ring was coated in sterile vacuum grease (Beckman Coulter) 
and then placed over a single colony to make a seal. The colony was subsequently 
seeded into a well on a 6-well dish via trypsinisation.  Cells were then grown in a 10 
cm dish until confluent.  
2.2.4 Dilution cloning 
Cells were seeded onto a 96-well plate with a theoretical 1 cell per well. When 
confluent, cells were seeded into a well on a 6-well dish. Cells were grown up to a 
confluent 10 cm dish. 
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2.2.5 Sanger sequencing  
Sanger sequencing for AR and EMX1 genes was performed by the Genomics and 
Bioinformatics Lab at the University of York using BigDye Terminator v3.1 Cycle 
Sequencing Kit from Applied Biosystems. Samples were run on an Applied Biosystems 
3130xl Genetic Analyser. Sequences were analysed by myself using SeqScanner 2. 
When edited sequences produced multiple peaks, which is indicative of edits in 
multiple alleles, CRISP-ID was used to analyse the sequences (Dehairs et al., 2016). 
CRISP-ID is a web application which allows the identification of indels in up to three 
different alleles from a single Sanger trace. 
2.3 Isolation and Analysis of Genomic DNA 
2.3.1 DNA extraction  
Genomic DNA (gDNA) was extracted using the Qiagen DNeasy Blood and Tissue Kit 
(Qiagen) following the manufacturer’s protocol from cell pellets. Briefly, up to 5x106 
were trypsinised and harvested. The cells were pelleted by stopping the trypsin in R10 
and centrifuging the cells at 1200 RPM for 3 min. The supernatant was aspirated, and 
the pellet was resuspended in 200 µl PBS. 20 µl of protinase K, 4 µl of RNase A and 
200 µl of ATL buffer was added and the lysate was vortexed. The lysate was incubated 
at 56 °C for 10 min. 200 µl of 100% ethanol was added to the lysate and it was mixed 
by vortex. The homogenate was transferred to a DNeasy Mini spin column in a 2 ml 
collection tube. The column was centrifuged at 8000 RPM for 1 min. The flow-through 
was discarded. 500 µl of AW1 buffer was added to the spin column and centrifuged 
at 8000 RPM for 1 min. The flow-through was discarded. 500 µl of AW2 buffer was 
added to the spin column and centrifuged at 13,000 RPM for 3 min. The spin column 
was transferred to a 1.5 ml microcentrifuge tube and 30 µl of nuclease-free water 
(Sigma-Aldrich) was added to the column to elute the gDNA. The column was 
centrifuged at 8000 RPM for 1 min and discarded. The concentration of the gDNA was 
determined by the NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific). 
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gDNA samples were stored at -20 °C.  gDNA was considered to be pure if the ratio 
between the 260nm and 280nm absorbance readings was ~1.8. 
2.3.2 PCR  
Polymerase chain reaction (PCR) was carried out on gDNA to amplify the region of AR 
and EMX1 genes targeted by the CRISPR/Cas9 lentivirus. PCR reagents were obtained 
from Promega and primers were manufactured by Sigma-Aldrich (Table 2.2). In each 
PCR reaction, between 100 ng – 200 ng of gDNA was added to a 50 µl reaction (5 µl 
gDNA and 45 µl master mix) and each reaction was run in a GeneAmp PCR System 
9700 thermal cycler (Applied Biosystems). 
2.3.2.1 AR master mix and PCR programme  
Promega 5x flexi buffer (1x), 25 mM MgCl2 (2.5 mM), 10 mM dNTPs (0.4 mM) 
(Invitrogen), 10 µM forward primer (0.2 µM), 10 µM reverse primer (0.2 µM), high-
performance GoTaq® G2 DNA Polymerase (2.5 U) and 26 µl of nuclease-free water to 
total 45 µl per sample (Table 2.2). The PCR programme used was as follows: 
1 hold: 94 °C, 2:00 min 
35 cycles:  94 °C, 30 sec 
      60 °C, 30 sec 
      72 °C, 30 sec 
2 holds: 72 °C, 5:00 min 
2.3.2.2 EMX1 master mix and PCR programme  
Promega 5x flexi buffer (1x), 25 mM MgCl2 (2.0 mM), 10 mM dNTPs (0.4 mM) 
(Invitrogen), 10 µM forward primer (0.2 µM), 10 µM reverse primer (0.2 µM), high-
performance GoTaq® G2 DNA Polymerase (2.5 U) and 27.5 µl of nuclease-free water 
to total 45 µl per sample (Table 2.2). The PCR programme used was as follows: 
1 hold: 94 °C, 2:00 min 
30 cycles:  94 °C, 30 sec 
      59 °C, 30 sec    
                 72 °C, 30 sec 
2 holds: 72 °C, 5:00 min 
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Table 2.2: Primers for PCR 
Target Product length Primer Sequence 
AR 424 bp 
Forward: AGCCTGTTGAACTCTTCTG 
Reverse: GTTGCTGTTCCTCATCCA 
EMX1 507 bp 
Forward: ATGGGAGCAGCTGGTCAGAG 
Reverse: CAGCCCATTGCTTGTCCCT 
2.3.4 PCR Purification  
PCR products were purified using the QIAquick PCR purificaition Kit (QIAGEN). Buffer 
PB was added to PCR products in a 1:5 ratio (v/v) and transferred to a QIAquick spin 
column. The samples were then centrifuged at 13,000 RPM for 1 min. The flow-
through was discarded and 750 µl of Buffer PE was added to wash the column. The 
samples were centrifuged at 13,000 RPM for 1 min and the flow-through was 
discarded. To elute the DNA, the column was transferred to a 1.5 ml microcentrifuge 
tube and 30 µl of nuclease-free water (Sigma-Aldrich) was added for 1 minute before 
centrifuging at 13,000 RPM for 1 minute. This step was repeated to total 60 µl of 
eluted DNA. The concentration was determined using a NanoDrop ND-1000 
spectrophotometer and samples were stored at -20 °C. 
2.3.5 Gel electrophoresis 
PCR products were visualised on a 1% (w/v) agarose (Invitrogen) gel stained with 
GelRed® 10,000X nucleic acid gel stain (Biotium) with a 100 base pair (bp) DNA ladder 
(New England Biolabs). The gels were run at 80 V for approximately 70 min and 
imaged with UV illumination on the Pxi system (Syngene).  
2.3.6 Copy number analysis of genomic AR 
The copy number of AR and DMD was investigated via qPCR in the cell lines BPH-1, 
BPH-1 PPmO, P4E6, VCaP as well as female and male DNA. GAPDH was used as an 
endogenous control. In each 15 µl reaction, 20 ng of gDNA was loaded. The 1x master 
mix consisted of 7.5 µl BioRad SSoFast EvaGreen Supermix, 0.6 µl of 10 nM forward 
primer, 0.6 µl of 10 nM reverse primer (Table 2.3) and 4.3 µl nuclease-free water. 
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Reactions were pipetted onto a FrameStar® 96 Well Skirted PCR Plate (4titude) sealed 
with an optically clear seal (BioRad) and spun at 1100 RPM at 4 °C for 2 min. The qPCR 
reaction was performed on the BioRad CFX machine with the programme as follows: 
(98 °C 2:00, 98 °C 0:05, 58 °C 0:05) x44 and a melt curve at 65 °C 0:05, 95 °C 0:50. The 
Ct method was used to analyse the relative expression of AR and DMD to GAPDH 
and the male control. For example for the BPH-1 cell line, Ct = CtAR – CtGAPDH and 
Ct = CtBPH-1 - Ctmale. Therefore 2-
Ct calculates the copy number of AR and DMD.   
Table 2.3: Primers for copy number analysis 
Target Primer Sequence 
AR 
Forward: TCATTATCAGGTCTATCAACTCTT  
Reverse: GTCATCCCTGCTTCATAACATTTC  
DMD 
Forward: TTGGTTGCCAGTTATGGGCT  
Reverse: CCAGCTGTCATGCAAAACCC  
GAPDH 
Forward: ATGCTGCATTCGCCCTCTTA  
Reverse: GCGCCCAATACGACCAAATC  
2.4 Isolation and Analysis of Protein Expression  
2.4.1 Protein extraction  
Harvested cells were resuspended in CytoBuster™ protein extraction reagent 
(Novagen) with cOmplete™ Mini EDTA-free Protease Inhibitor Cocktail (Roche). The 
lysates were incubated at room temperature for 5 min and then centrifuged at 16,000 
g for 4 min at 4 °C. The supernatant was collected and stored at -80 °C. 
2.4.2 Bicinchoninic acid assay (BCA) for protein concentration 
determination 
The protein lysate concentration was quantified using the BCA protein assay kit 
(Thermo Scientific) according to the manufacturer’s instructions. BSA standards and 
samples were pipetted in triplicate into a 96 well plate. Working reagent was added 
to each well and the plate was incubated at 37 °C for 30 min. The absorbance was 
read on a POLARstar OPTIMA microplate reader (BMG labtech) at 562 nm. A standard 
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curve of known protein concentrations was generated to determine the concentration 
of the unknown samples. 
2.4.3 SDS-PAGE gel electrophoresis  
Protein lysate (20 µg) was added to 4x Laemmli Sample Buffer (Bio-Rad) and heated 
to 100 °C for 4 min in a QBD2 heating block (Grant). Samples were loaded onto 10% 
Tris-SDS acrylamide gels along with Precision Plus Protein™ Kaleidoscope™ 
Prestained Protein Standards (Biorad). The gels were run at 80 V for 2 hr in SDS 
running buffer (3.5 mM SDS, 0.19 M Glycine, 25 mM Tris).  
2.4.4 Western blotting 
Table 2.4: Primary and secondary antibodies for AR and GAPDH western blots 
The resolved proteins were transferred onto Immobilon-P membrane (Millipore) pre-
treated with methanol in transfer buffer (48 mM Tris, 39 mM Glycine, 10% (v/v) 
Methanol) at 100 V for 1.5 hr. Immediately after, membranes were blocked in 5% non-
fat milk in 0.1% Tris-buffered saline-tween (TBST) (150 mM NaCl, 50 mM Tris/HCl, pH 
7.5, 0.1% (v/v) Tween) for 1 hr at room temperature. The membranes were then 
 Antibody 
Product 
Size 
(KDa) 
Working 
dilution 
Species 
Isotype 
Manufacturer Cat. No. 
P
ri
m
a
ry
 A
n
ti
b
o
d
ie
s 
Anti-AR 110 1:750 
Rabbit 
polyclonal 
Santa Cruz sc-815 
Anti-
GAPDH 
37 1:10000 
Rabbit 
polyclonal 
abcam ab9485 
S
e
c
o
n
d
a
ry
 A
n
ti
b
o
d
y
 
Anti-
Rabbit 
IgG, HRP-
linked 
Antibody 
N/A 1:10000 Goat 
Cell Signalling 
Technology 
7074 
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incubated with primary antibodies diluted in 1% non-fat milk at 4 °C overnight (Table 
2.4).  Membranes were washed three times for 5 min each in TBST and then incubated 
in the secondary antibody, diluted in 1% non-fat milk for 1 hr at room temperature. 
Membranes were washed again three times in TBST. Chemiluminescent detection was 
performed using the BM Chemiluminescence Blotting Substrate (POD) system 
(Roche). The proteins were visualised using ECL hyperfilm (Amersham) and processed 
using the Kodak GBX developer and fixer solutions (SLS). 
2.5 In vitro Differentiation of Prostate Epithelial Cells  
2.5.1 Development of an epithelial bilayer  
BPH-1 and BPH-1 PPmO cells were seeded at 100% confluency (4x105) onto a 12 well 
plate in triplicate. They were grown in non-differentiating media (R5) and 
differentiating media (D5 with 10 nM DHT). After two weeks, the expression of 
mOrange was analysed using flow cytometry on a Cytoflex S (Beckman Coutler). 
mOrange fluorescence excitation wavelength is 548 nm and the emission wavelength 
is 562 nm, therefore a 561 nm laser was used. Debris was excluded using FS Area/ SS 
Area. Doublets were excluded using FS Area/FS Width. mOrange positive cells were 
gated on ECD Area/ PE Area. 
2.5.2 3D co-Culture of prostate spheroids 
BPH-1 PPmO and P4E6 cells were grown into 3D spheroids under conditions 
previously optimised in our lab. The stromal cells used in this study were obtained 
from the CRU bio-bank of primary cultures. The cells were harvested from human 
prostate tissue obtained, with patient consent and full ethical approval and were from 
patients undergoing radical prostatectomy and channel transurethral resection 
(TURP) for prostate cancer (ethics number: 07/H1304/121). Stromal cells were seeded 
at a density of 2x105 in 6 well plates, in DMEM with 10% FCS (D10) and 10 nM DHT 
(Sigma-Aldrich) and were grown until 70-80% confluent. To set up the co-culture, 2 
ml of MatrigelTM (Corning) was added to 0.4 µM inserts (Falcon) at a ratio of 1:1 with 
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2 ml of K2 medium.  This MatrigelTM plug was incubated at 37 °C for 30 min. 1.5x105 
of BPH-1 PPmO and P4E6 cells were resuspended in 50% MatrigelTM:K2 media 
supplemented with 10 nM DHT, 10 nM -estradiol and 2 mM CaCl2 (Sigma-Aldrich) 
and  seeded on to the MatrigelTM plug. The MatrigelTM was allowed to set for 30 min 
37 °C and 1 ml of the supplemented K2 media was subsequently added to the insert. 
To maintain the spheroids, 500 µl of spent epithelial media was aspirated and replaced 
with 500 µl of fresh media on alternate days. The stromal cells were fed on those days 
with 2 ml of stromal media. The spheroids and stromal cells were grown for up to 14 
days.   
2.5.2.1 Quantification of mOrange Expression  
Spheroids were visualised on a Leica DMIL LED fluorescent microscope. The total 
number of spheroids and the number of spheroids expressing mOrange were counted 
in four random fields of view. The percentage of mOrange spheroids was calculated.  
2.6 Detection of AR  Expression 
2.6.1 Spheroid cell recovery 
Spheroids were harvested from MatrigelTM to form a pellet using Cell Recovery 
Solution (Corning). Initially the spent media was collected and transferred to an ice-
cold 15 ml falcon tube. 2 ml of Cell Recovery Solution was added to and a cell lifter 
was used to break up the MatrigelTM. The mixture was transferred to the 15 ml falcon 
tube. A further 4 ml of Cell Recovery Solution was added and the remaining MatrigelTM 
was transferred to the 15 ml falcon tube. The falcon tube was then mixed for 1 hr in 
ice on a rocker. The falcon tube was centrifuged for 5 min at 300 g at 2 °C. The 
supernatant was aspirated, and the pellet was washed by resuspending it in 1 ml of 
ice-cold PBS. The mixture was centrifuged for 5 min at 300 g at 2 °C. This step was 
repeated, and the final pellet was stored at -20 °C. 
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2.6.2 RNA extraction 
RNA was extracted from cell and spheroid pellets using an RNeasy Mini Kit (Qiagen) 
as per the manufacturer’s instructions. Spheroid pellets were collected as described 
in section 2.6.1. Cell pellets were harvested via trypsinisation. The trypsin-EDTA was 
stopped with R10 and the cells were centrifuged at 1200 RPM for 3 min. The 
supernatant was aspirated, and the pellet was lysed with 350 µl of Buffer RLT with 
1:100 (v/v) β-mercaptoethanol (β-Me) and vortexed for 20 seconds. To homogenise 
the samples, the lysate was transferred to QIAshredder spin column (Qiagen) and 
centrifuged at 13,000 RPM for 2 min. Then 350 µl of 70% ethanol was added and the 
homogenate was transferred to a RNeasy Mini spin column. The mixture was 
centrifuged at 10,000 RPM for 1 min. The flow-through was discarded and the column 
was washed with 700 µl of RW1 Buffer. The mixture was centrifuged at 10,000 RPM 
for 1 min. The flow-through was discarded and the column was washed with 500 µl 
of RPE Buffer. The mixture was centrifuged at 10,000 RPM for 1 min. The flow-through 
was discarded and the column was washed again with 500 µl of RPE Buffer. The 
mixture was centrifuged at 10,000 RPM for 2 min and the flow-through was discarded. 
The column was dried by centrifuging at 10,000 RPM for 1 min in a new collection 
tube. Each column was then placed in a 1.5 ml microcentrifuge tube and 30 µl of 
RNase free water was added to elute the RNA. The microcentrifuge was left for 1 
minute before centrifuging at 10,000 RPM for 1 min. This step was repeated again to 
result in a final elution of 60 µl. RNA quality and concentration was then determined 
using NanoDrop ND-1000 spectrophotometer. The RNA samples were stored at -20 
°C. 
2.6.3 cDNA synthesis  
All RNA samples were reverse transcribed into complementary DNA (cDNA). Two 
master mixes were made (Invitrogen) according to Table 2.5. In a PCR tube the 
appropriate volume of RNA was added, 2 µl of master mix 1 and then the mixture was 
made up to 13 µl with nuclease-free water (Sigma-Aldrich). The mixture was incubated 
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at 65 °C for 5 min. The tubes were put on ice for 2 min and then 7 µl of master mix 2 
was added. The tubes were then incubated at 23 °C for 10 min. 55 °C for 10 min and 
80 °C for 10 min. This was conducted using a GeneAmp PCR Sytem 9700 (Applied 
Biosystems). The PCR product was then purified as described in section 2.3.4 and the 
concentration was determined using NanoDrop ND-1000 spectrophotometer. 
Table 2.5: cDNA synthesis master mixes 
 Component Volume 
M
a
st
e
r 
M
ix
 1
 50 µM random primers 1 µl 
10 mM dNTP mix 1 µl 
RNA (up to 5 ug) up to 11 µl 
Nuclease-free water to 13 µl 
M
a
st
e
r 
M
ix
 2
 
5x SSIV Buffer 4 µl 
100 mM DTT 1 µl 
RNase OUTTM 1 µl 
Superscript® IV reverse 
transcriptase (200 U/µl) 
1 µl 
 
2.6.4 Quantitative reverse transcriptase (qRT-PCR) detection of AR 
mRNA 
Quantitative reverse transcriptase PCR (qRT-PCR) was performed using a CFX96 Real-
Time PCR Detection System (Bio-Rad). SYBR Green chemistry was used with 5 µl 
SsoFast EvaGreen Supermix (Bio-Rad), 0.9 µl 10 nM forward primer, 0.9 µl 10 nM 
reverse primer and 1.2 µl Sigma water (Table 2.6). 2 µl cDNA (5 µg/ml) was added on 
the bench top to total 10 µl per reaction. Reactions were pipetted onto a FrameStar® 
96 Well Skirted PCR Plate (4titude) sealed with an optically clear seal (BioRad) and 
spun at 1100 RPM at 4 °C for 2 min. The qPCR reaction was performed on the BioRad 
CFX machine with the programme as follows: (95 °C 2:00, 95 °C 0:10, 60 °C 0:05) x39 
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and a melt curve at 65 °C 0:05, 95 °C 0:50.  The standard curve method was used to 
determine the fold difference in expression between the calibrator sample and 
unknown samples. The results were analysed using the Bio-Rad CFX Manager 2.  
Table 2.6: Primers for qRT-PCR 
Target Primer Sequence 
AR 
Forward: CTCATGCCCCCTTTCAGATGTC 
Reverse: GAAAAAAAAAGCCCAGCAAATAGAAT 
RPLPO 
Forward: GCACTGGAAGTCCAACTACTTC 
Reverse: TGAGGTCCTCCTTGGTGAACAC 
2.7 Paraffin-embedding and Sectioning of Prostate 
Spheroids  
2.7.1 Collection and preparation of spheroids  
The media and MatrigelTM containing spheroids was transferred to a 15 ml falcon tube 
using a Pasteur pipette. 1 ml of PBS was added to the remaining MatrigelTM and 
transferred to the falcon tube using a Pasteur pipette. The MatrigelTM was spun at 
1500 RPM for 5 min. The supernatant was aspirated, and the pellet was washed 5 
times with PBS. The pellet was resuspended in 225 µl of citrate-plasma and 5.6 µl of 
1 M calcium chloride. Following this, 22.5 µl of thrombin is added and the mixture is 
stirred gently with a pipette until coagulation. The coagulated pellet was moved to a 
histocassette which is made up of a layer of filter paper, a sponge layer with a hole 
for the pellet and a layer of filter paper on top. The histocassette was left in 4% 
formaldehyde for 4 hr and then stored in 70% ethanol until paraffin embedding.  
2.7.2 Paraffin-embedding spheroids 
When the spheroids are ready for paraffin embedding they were transferred in the 
histocassette to fresh 70% ethanol for 10 min. This was followed by 100% ethanol 3 x 
10 min, propan-2-ol 2 x 10 min and xylene 4 x 10 min. The histocassettes were blotted 
on blue roll and then placed into melted paraffin pots 4 x 15 min. The paraffin was 
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kept at 60 °C and melted the night before. The spheroid pellet was then removed 
from the histocassette and placed into a metal mould filled with molten paraffin. The 
lid of the histocassette was placed on top containing the label, and then left to harden 
on the cold plate for up to 20 min. The samples were removed from the mould and 
stored and room temperature before sectioning.  
2.7.3 Sectioning spheroids 
SuperFrost Plus Slides (ThermoFisher Scientific) used for sectioned spheroids were 
initially coated in 3-Aminopropyltriethoxysilane (APES) before use. They were 
submerged in a 2% APES bath for 3 min followed by washes in acetone and then 
distilled water. They were left to dry overnight on a slide dryer.  
The paraffin-embedded spheroids were sectioned (5 µm thick) using a Leica RM2235 
microtome. A water bath was used to flatten the paraffin sections onto APES coated 
slides. They were left to dry overnight on a slide dryer. 
2.8 Immunohistochemistry of spheroids  
On a slide dryer, the paraffin-embedded spheroid and cell pellet sections were baked 
at 45 °C for 20 min. Paraffin was removed and the sections were rehydrated by 
immersing the slides in the following baths: xylene 2 x 10 min, xylene 2 x 1 min, 100% 
ethanol 3 x 1 min and 70% ethanol 1 x 1 min. The slides were then washed under 
running tap water for 5 min. Heat-induced epitope retrieval (HIER) was conducted 
over night using the 2100 Antigen Retriever (Aptum Biologics) with the slides 
immersed in sodium citrate buffer (pH 6).  
The slides were washed with PBS 3 x 5 min at medium speed on an orbital shaker the 
following day. Using a PAP pen (Dako), a circle was drawn around each section to 
form a hydrophobic barrier. The sections were then blocked in 10% (v/v) FCS in PBS 
for 1 hr at room temperature in a dark and moist box. The block was removed with a 
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PBS wash and the sections were incubated in primary antibody (Table 2.7) diluted in 
10% (v/v) FCS in PBS overnight at 4 °C in the box.  
The next day the slides were washed with PBS 3 x 5 min. Endogenous peroxidases 
were removed by treating the sections with 3% (v/v) hydrogen peroxidase in PBS for 
30 min. The hydrogen peroxidase was washed off with PBS. The slides were then 
incubated with the secondary biotinylated antibody (Table 2.7) diluted in 10% (v/v) 
FCS in PBS for 30 min at room temperature. The slides were washed again with PBS 3 
x 5 min to remove the secondary antibody. The sections were then incubated with the 
tertiary antibody (Table 2.7) (streptavidin-HRP) diluted in 10% (v/v) FCS for 30 min at 
room temperature. The tertiary antibody was removed by washing with PBS for 2 x 5 
min. The sections were incubated in diaminobenzidene (ImmPACT DAB peroxidase 
substrate, Vector Laboratories) for 90 sec. The slides were rinsed in distilled water and 
then running water for 5 min. The sections were subsequently counterstained with 
haematoxylin for 3 sec and then rinsed with running water for 5 min. Finally, the 
sections were dehydrated by immersion in the following baths: 70% ethanol 1 x 1 min, 
100% ethanol 3 x 1 min and xylene 2 x 1 minute. A coverslip was mounted onto each 
slide using DPX (Sigma-Aldrich).  
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Table 2.7: Antibodies used for IHC 
 
Antibody 
Working 
Dilution 
Species Manufacturer Cat. No. 
P
ri
m
a
ry
 
CK5 1:500 
Rabbit 
monoclonal 
Abcam Ab52635 
p63 1:500 
Mouse 
monoclonal 
Dako M7317 
CK18 1:800 
Mouse 
monoclonal 
Sigma-Aldrich C8541 
NKX3.1 1:500 
Rabbit 
monoclonal 
Cell Signalling D6D2Z 
AR 1:100 
Mouse 
monoclonal 
Santa-Cruz 441 
S
e
c
o
n
d
a
ry
 
Goat anti-
rabbit 
biotinylated 
1:500 
Goat 
polyclonal 
Dako E0432 
Rabbit anti-
mouse 
biotinylated 
1:200 
Rabbit 
polyclonal 
Dako E0354 
T
e
rt
ia
ry
 
Streptavidin-
HRP 
1:100 N/A Dako P0397 
2.9 Cell Viability Assay  
BPH-1 PPmO and P4E6 spheroids were set up in triplicate as described in section 2.5.2 
on a 0.4 µm insert (Millicell) in a 24 well plate (Corning) and left to grow for 8 days. 
The day before the CellTiter-Glo® 3D cell viability assay (Promega) was conducted, the 
working reagent was moved from -20 °C to 4 °C and left overnight to thaw. The next 
day, the working reagent was placed at room temperature along with the plate of 
spheroids for 30 min. ATP (Sigma-Aldrich) was diluted in water to produce standards 
at 50 µM, 10 µM, 2 µM, 0.4 µM, 0.08 µM, which were plated in triplicate at 100 µl onto 
an opaque bottom 96 well plate (Nunc). 100 µl of the working reagent was added to 
each well of spheroids and ATP standards. The plates were mixed on an orbital shaker 
for 5 min at maximum speed. 200 µl of the media and working reagent mix from the 
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spheroids was then plated onto the 96 well plate. Luminescence was recorded on a 
POLARstar OPTIMA microplate reader (BMG labtech). A standard curve of known ATP 
concentrations was generated to determine the concentration in the spheroids to 
determine their viability.  
2.10 Statistical Analyses  
All statistical tests were carried out using Graph Pad Prism 7 software (San Diego, 
USA). Results were displayed as a mean of three technical replicates with associated 
standard deviation. Statistical significance was represented on graphs as * p = 0.01 to 
0.05, ** p = 0.001 to 0.01, *** p = 0.0001 to 0.001, **** p < 0.0001. 
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3. Results 
3.1 Generation of AR  Knock-Out in Basal Prostate Cells 
3.1.1 Basal cell lines contain one or more copies of AR 
Prior to the CRISPR/Cas9 experiments, the number of AR copies within BPH-1, BPH-1 
PPmO and P4E6 cell lines needed to be determined. The original karyotype of the 
BPH-1 cell line suggested there would be two copies of AR due to the presence of 
two X chromosomes (Hayward et al., 1995). However the number of copies of AR is 
unknown in BPH-1 PPmO cells.  
Copy number analysis was conducted via qPCR of gDNA from different cell lines. Copy 
number was normalised to GAPDH and then to male cells. DMD was used to 
distinguish between ploidy and amplification of AR because DMD is not near AR on 
the X chromosome and therefore it is unlikely that it will be amplified. Hence, DMD is 
used as a proxy for the number of X chromosomes. Female and male gDNA were used 
as controls for two X chromosomes and one X chromosome respectively. VCaP cells 
were used as a positive control as their AR copy number has been previously 
determined (Li et al., 2012). The analysis showed that P4E6 cells have one X 
chromosome and one copy of AR (Figure 3.1). BPH-1 cells have two X chromosomes 
and two copies of AR. BPH-1 PPmO cells have three X chromosomes and three copies 
of AR. The comparison of AR copy number to DMD copy number is not significantly 
different for any cell lines expect for VCaP (paired t-test, p=0.0441).  
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Figure 3.1: AR and DMD copy number varies in different prostate cell lines. qPCR was 
used to analyse the copy number of AR and DMD in the gDNA of different prostate cell lines. 
Male and female gDNA were used as controls.  Paired t-test, * = p ≤ 0.05, n=3. Error bars 
represent standard deviation calculated from the coefficient of variation.  
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3.1.2 Determination of minimal lethal dose of puromycin 
The CRISPR/Cas9 lentivirus cassette contained the resistance gene for the antibiotic 
puromycin. Initially the minimal lethal dose (MLD) of puromycin was determined for 
both BPH-1 and BPH-1 PPmO cells. This was defined as the minimum concentration 
required to kill all the cells. Following 7 days of exposure to increasing concentrations 
of puromycin (0.25 μg/ml to 2.0 μg/ml) cells were stained with 1% crystal violet in 
order to visualise the remaining cells. It was concluded that the MLD of puromycin for 
BPH-1 and BPH-1 PPmO cells was 1.0 μg/ml (Figure 3.2). Previous work done in our 
lab showed that the MLD for P4E6 cells was 2.0 μg/ml (unpublished). 
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Figure 3.2: Minimum lethal dose of puromycin for BPH-1 and BPH-1 PPmO cells. 
Puromycin was added to BPH-1 (A) and BPH-1 PPmO (B) cells for 7 days in concentrations 
ranging from 0 µg/ml to 2.0 µg/ml. The cells were stained with 1% crystal violet. 
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3.1.3 PCR Optimisation of AR  primers 
In order to determine if the CRISPR/Cas9 had successfully edited AR, primers were 
designed to flank the gRNA target sequence and the subsequent PCR products were 
sequenced. This required optimisation of PCR conditions to produce a single product 
suitable for sequencing. Initially a range of concentration from 1 mM to 2.5 mM of 
MgCl2 was used. VCaP gDNA was used as a positive control and the primers were 
tested on BPH-1 gDNA. It was determined that the optimal concentration of MgCl2 
was 2.0 mM due to this being the minimum concentration for bands to appear (Figure 
3.3).  
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Figure 3.3: Optimisation of PCR conditions for AR primers. Electrophoresis gel showing 
bands detecting AR at 424 bp. MgCl2 concentrations where varied from 1.0 mM to 2.5 mM. B: 
BPH-1 gDNA. V: VCaP gDNA. - : water  
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3.1.4 CRISPR/Cas9 successfully produced AR KO clones in basal 
prostate cell lines 
The BPH-1, BPH-1 PPmO and P4E6 cell lines were incubated with the CRISPR/Cas9 
lentivirus targeting exon 1 of the AR gene for 12 hours (Figure 3.4). The transduced 
cells were selected using puromycin for 2 weeks. Between 18 – 22 individual clones 
were isolated using ring and dilution cloning. A PCR, with primers flanking the gRNA 
target sequence in exon 1 of AR, was then conducted and the products were 
sequenced (Figure 3.5C). The sequences were analysed for multiple alleles using 
CRISP-ID (Dehairs et al., 2016). Nucleotide and protein sequences were aligned to the 
WT using the Needleman-Wunsch algorithm. Homozygous edits were defined as the 
same sequence modifications occurring in all alleles of AR on the X chromosome. 
Heterozygous edits were defined as multiple alleles having modifications and hence 
different amino acid sequences being produced, but no WT sequence was identified. 
Non-edited clones were defined when the sequence was purely WT. Partially edited 
clones were defined when there were some modifications, but a WT sequence was 
still identified (Figure 3.5A). CRISPR/Cas9 editing was successful in all three cell lines: 
BPH-1, BPH-1 PPmO and P4E6 (Table 3.1). All successful ARKO clones were viable and 
proliferated in standard cell culture. 
Table 3.1: Summary of AR CRISPR/Cas9 clones 
 BPH-1 BPH-1 PPmO P4E6 
Homozygous edited clones 0 0 7 
Heterozygous edited clones 7 6 6 
Non-edited clones and partially 
edited clones 
11 14 9 
Total number of clones 18 20 22 
Percentage of clones edited 39% 30% 59% 
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Figure 3.4 A work flow of the CRISPR/Cas9 experimental set up. Cells transduced with 
CRISPR/Cas9 lentivirus were selected using puromycin. Single cell clones were generated using 
ring cloning or dilution cloning. DNA was extracted and the PCR product for the target gene 
was sequenced. 
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The positive control which was initially used was a lentivirus which targeted EMX1. The 
EMX1 gene encodes a transcription factor which helps control brain development 
(Chan et al., 2001). This was a lentivirus positive control recommended by Sigma-
Aldrich for CRISPR/Cas9 experiments that should have no impact on AR expression. 
However, qRT-PCR showed that AR expression was knocked down in these clones 
(data not shown). Multidimensional scaling of other EMX1 KO clones in the lab 
conducted by Leanne Archer showed that there was a large variation in total gene 
expression between multiple clones. Therefore, the EMX1 KO clones were not a 
suitable positive control. Instead clones which were treated with the AR targeted 
lentivirus but did not have any genetic edits were used as the positive control. 
Hereafter these clones will be referred to as the lentivirus control.   
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Figure 3.5 The use of CRISPR/Cas9 to KO AR in prostate cell lines. (A) Sanger sequences 
showing examples of a non-edited clone, a partially edited clone, a homozygous edited clone 
and a heterozygous edited clone. The yellow arrows show where the first change in the genetic 
sequence occurs. (B) CRISPR/Cas9 lentivirus vector map designed by Sigma-Aldrich. (C) The 
CRISPR/Cas9 gRNA (blue) targets the beginning of exon 1 (brown) and with the primers 
designed to span the gRNA target (green).  
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Initial AR CRISPR/Cas9 experiments were conducted on BPH-1 cells to test the 
effectiveness of the lentivirus and to optimise the method of cloning (Figure 3.6). Two 
dosages were tested; AR1 (1 lentivirus to 1 cell) and AR2 (2 lentiviruses to 1 cell). Both 
dosages resulted in the AR targeting lentivirus successfully transducing to produce 
puromycin resistant cells (Figure 3.6A). The CRISPR/Cas9 was 39% effective, with seven 
of the clones possessing heterozygous edits (Table 1 and Figure 3.6B). There were no 
homozygous edits generated. The selected clones were formed from a mixture of ring 
and dilution cloning (Figure 3.4). Clones generated in further CRISPR/Cas9 
experiments were selected using dilution cloning. This is due to ring cloning having a 
higher risk of infection and the difficulty of isolating a single colony.  
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Figure 3.6: BPH-1 cell line AR CRISPR/Cas9 experiment. (A) Images of the cells that were 
treated with puromycin (+) and those that were not treated with puromycin (-). AR1: AR 
CRISPR/Cas9 lentivirus 1:1 dosage (lentivirus:cell). AR2: AR CRISPR/Cas9 lentivirus 2:1 dosage. 
PBS: no CRISPR/Cas9 lentivirus. (B) An example of an edited clone sequence in comparison to 
the WT sequence. Yellow arrow represents the start of the edited sequence. 
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CRISPR/Cas9 was then conducted on BPH-1 PPmO cells. These were a more elegant 
model to monitor differentiation in comparison to BPH-1 cells, due to the presence 
of the PSA-Probasin promoter which fluoresces mOrange when AR is expressed in 
luminal cells. Lentivirus transduction was successful and puromycin resistant cells 
were produced. There were more puromycin resistant cells at the AR2 dosage than 
the AR1 dosage of the AR targeting CRISPR/Cas9 lentivirus (Figure 3.7A). Therefore, 
the AR2 dosage was used for subsequent CRISPR/Cas9 experiments.  
Despite BPH-1 PPmO having three copies of AR, six clones were successfully edited 
to give a heterozygous KO (Table 1 and Figure 3.7C). In particular, clones 19 and 13 
had the largest changes to the AR gene, as seen by multiple bands on the 
electrophoresis gel (Figure 3.7B).  CRISP-ID identified three different alleles from both 
clone 13 and clone 19 (Figure 3.7C). AR -/-/- KO clone 13 (ARKO13) had a range of 7-
15 bp deletions, hence producing smaller PCR products (Figure 3.7B). Whereas AR -/-
/- KO clone 19 (ARKO19) had large insertions, hence producing the larger PCR 
products (Figure 3.7B). All of the amino acid sequences generated from ARKO19 and 
ARKO13 had early stop codons and did not produce the PolyQ motif due to frame 
shifts disrupting the CAG repeat (Figure 3.7C).   
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Figure 3.7: BPH-1 PPmO cell line AR CRISPR/Cas9 experiment. (A) Images of the cells that 
were treated with puromycin (+) and those that were not treated with puromycin (-). AR1: AR 
CRISPR/Cas9 lentivirus 1:1 dosage (lentivirus:cell). AR2: AR CRISPR/Cas9 lentivirus 2:1 dosage. 
PBS: no CRISPR/Cas9 lentivirus. (B) Electrophoresis gel detecting AR in 20 ARKO clones with 
ARKO13 and ARKO19 clones producing multiple bands.  (C and D) The base sequence changes 
(top) and amino acid changes (bottom) of the heterozygous clones ARKO13 (C) and ARKO19 
(D) using CRISP-ID and multisequence alignment.   
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P4E6 cells were then targeted by CRISPR/Cas9 to investigate the role of AR in early 
stage PCa. Similarly to the previous CRISPR/Cas9 experiments, the P4E6 cells 
transduced with the lentiviruses were puromycin resistant (Figure 3.8A). Due to P4E6 
only having a single copy of AR, seven homozygous clones were produced (Table 3.1). 
AR - KO clone 22 (ARKO22) and AR - KO clone 15 (ARKO15) both had small insertions 
(1 bp and 4 bp respectively) which resulted in frame shifts, causing early stop codons 
in the amino acid sequences (Figure 3.8B and C). In particular ARKO22 is predicted to 
produce a product that is 22 amino acids long instead of 920 amino acids in the WT 
form (Figure 3.8C).  
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Figure 3.8: P4E6 cell line AR CRISPR/Cas9 experiment (A) Images of the cells that were 
treated with puromycin (+) and those that were not treated with puromycin (-). AR2: AR 
CRISPR/Cas9 lentivirus 2:1 dosage. PBS: no CRISPR/Cas9 lentivirus.  (B and C) The base 
sequence changes (top) and amino acid changes (bottom) of the homozygous clone ARKO15 
(B) and ARKO22 (C) using multisequence alignment. Green box: gRNA sequence. Red boxes: 
sequence changes.  
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3.2 Inducing Differentiation of Basal Cells into Luminal 
Cells 
3.2.1 Basal cell lines do not express AR  
A western blot was carried out to confirm whether BPH-1, BPH-1 PPmO and P4E6 
basal cells express AR protein when cultured in 2D in their normal growth media. 
GAPDH was used as a loading control and LNCaP cell lystate was used as a positive 
control for AR. BPH-1, BPH-1 PPmO and P4E6 cells do not express detectable AR 
protein (Figure 3.9). Therefore, they must be induced to differentiate into luminal cells 
to induce the expression of AR.  
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Figure 3.9: Basal cell lines do not express AR protein when undifferentiated. A western 
blot probed for AR and GAPDH in different prostate cell lines.  
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3.2.2 Growth in DHT for 24 hr is insufficient to induce full length AR 
expression  
Initially to induce differentiation VCaP, BPH-1 WT and BPH-1 ARKO clones were 
incubated with DHT for 24 hr while in 2D culture. The DHT activates the AR genomic 
signalling pathway and hence differentiation. A western blot was carried out to 
determine if AR expression was induced (Figure 3.10). VCaP cells over express AR and 
there was no difference in the levels of expression when VCaP cells were grown in 
DHT. There was no full length AR expression seen for BPH-1 WT cells or BPH-1 ARKO 
clones 1 and 2 (ARKO1 and ARKO2), both with and without DHT. These results 
demonstrate that either growth in DHT is not sufficient to push basal BPH-1 cells into 
differentiation and hence expression of full length AR or the sensitivity of the western 
blot is not enough to detect rare cells that might have differentiated.  
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Figure 3.10: Addition of DHT to induce differentiation in BPH-1 cells. A western blot 
probed for AR and GAPDH in cells treated with 10 nM DHT (+) for 24 hr or grown in normal 
media (-). VCaP was used as a positive control. ARKO1 and ARKO2 are BPH-1 AR KO clones 
created by CRISPR/Cas9. BPH-1 has not been treated with CRISPR/Cas9.  
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3.2.3 Culturing cell lines into a bilayer is insufficient to induce 
differentiation  
Previously in our lab, primary epithelial cells were induced to differentiate by allowing 
them to proliferate to become overconfluent. This resulted in two layers of adherent 
cells which mimicked the prostate epithelial bilayer (Frame et al., 2010, Swift et al., 
2010). This method of differentiation has not been used with cell lines, and therefore 
it was tested with BPH-1 and BPH-1 PPmO cells.  
WT BPH-1 and BPH-1 PPmO cells were left to grow for 2 weeks in differentiating 
media (DMEM + 5% FCS with 10 nM DHT) and normal growth media (RPMI + 5% 
FCS). When the cells were grown in differentiating media, a larger number of cells 
formed two-layers, mimicking an epithelial bilayer (Figure 3.11A). mOrange 
fluorescence from BPH-1 PPmO cells can be used as a proxy for PSA expression (a 
luminal cell marker) and hence late stages of differentiation. There appeared to be 
more mOrange fluorescence when more BPH-1 PPmO formed a bilayer in 
differentiating media than when grown in normal media (Figure 3.11A). Flow 
cytometry was carried out to quantify the number of differentiated bilayer cells (cells 
fluorescing mOrange) in comparison to monolayer cells in both media conditions. 
There was no difference between BPH-1 PPmO bilayer cells grown in normal media 
than in differentiating media (6.56% and 6.85% respectively) (Figure 3.11B). There was 
half the number of cells expressing mOrange in bilayer than there was in monolayer 
(12.84% compared to 6.56-6.85%) (Figure 3.11B). Therefore this method does not 
produce a large number of differentiated cells and other methods were investigated.  
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Figure 3.11: Growing cells into a bilayer does not push cells into differentiation. (A) 
Images of BPH-1 cells, BPH-1 PPmO cells and BPH-1 PPmO cells fluorescing mOrange in 
normal (R5) and differentiating media (D5 and 10nM DHT) for two weeks. (B) Flow cytometry 
analysis of mOrange fluorescence of BPH-1 and BPH-1 PPmO cells grown into a monolayer in 
normal media (top) and BPH-1 PPmO cells grown into a bilayer in normal and differentiating 
media (bottom). Scale bar = 400µm 
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3.2.4 Co-culturing basal cells with stroma to form 3D spheroids 
induces differentiation and AR expression  
Previously in our lab, prostate basal cell lines have been induced to differentiate by 
growing them into 3D spheroids in co-culture with stroma (Lang et al, 2001a). The 
spheroids have an acini-like structure with a central lumen surrounded by a basal and 
luminal layer (Figure 3.12C). This mimics the structure of prostate glands found in 
human tissue (Figure 3.12B). The epithelial cells are embedded in MatrigelTM above a 
MatrigelTM plug within an insert. The insert sits above a layer of stromal cells, which 
release growth factors (Figure 3.12A).  
Initially BPH-1 PPmO and P4E6 WT cells were grown in 4% MatrigelTM above a 50% 
MatrigelTM plug. The majority of the cells grew in a monolayer and was therefore not 
sufficient to induce 3D spheroids (Figure 3.12D). Therefore, the assay was optimised 
by growing the cells in 50% MatrigelTM above a 50% MatrigelTM plug which allowed 
no monolayer growth (Figure 3.12E). It was found that growing the spheroids for 7-
10 days was the optimum length of time to allow structure to develop. If the spheroids 
were grown for 14 days it resulted in cell death and low-quality RNA (not shown).  
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Figure 3.12: Optimisation of prostate spheroids in co-culture with stroma (A) Co-culture 
experimental set up for growing prostate spheroids.  (B) Prostate glands contain an inner 
luminal layer (NKX3.1 marker, green) and an outer basal layer (p63 marker, red), surrounded 
by stroma (image from Dr Frame). (C) Representative image of prostate spheroids from this 
project (P4E6 spheroid). (D) Spheroids embedded in 4% MatrigelTM. (E) Spheroids embedded 
in 50% MatrigelTM. Scale bar = 400 µm. 
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3.2.4.1 The effects of calcium on differentiation and AR expression 
The presence of calcium has been shown to help initiate differentiation in 
keratinocytes (Pillai et al., 1990). Therefore, the effects of growing BPH-1 PPmO and 
P4E6 spheroids in calcium was investigated. There were no apparent morphological 
differences when both P4E6 and BPH-1 PPmO spheroids were grown in calcium after 
7 days (Figure 3.13A). BPH-1 PPmO spheroids underwent differentiation with and 
without calcium, indicated by the fluorescence of mOrange. mOrange fluorescence 
was predominantly seen in the centre of the spheroid, where the luminal cells would 
be present. mOrange fluorescence was also seen scattered throughout the spheroid 
but at very specific locations, demonstrating that differentiation is occurring in 
individual cells rather than the spheroid as a whole (Figure 3.13A). This is reminiscent 
of the formation of a bilayer in vivo. The quantification of mOrange fluorescence  from 
BPH-1 PPmO cells (by counting the number of cells by fluorescence microscopy) 
showed that at day 4 there were significantly more differentiated spheroids when 
grown in the presence of calcium (19.9% with calcium, 12.4% without calcium, 
p=0.0478, unpaired t-test). However, by day 7 the presence of calcium made no 
difference to the number of differentiated spheroids (23.2% with calcium, 23.8% 
without calcium, p=0.6324, unpaired t-test) (Figure 3.13B).  
Subsequently the role of calcium on AR expression in spheroids was investigated 
using qRT-PCR. The primers were located in exon 9 and relative expression of AR 
mRNA was calculated by comparing to the mRNA levels of the endogenous control 
RPLPO in each sample. The fold difference was then calculated by comparing the 
relative expression of AR in each sample to PC3, which was the calibrator sample. This 
is referred to as the ΔΔCt method. LNCaP RNA was used as a positive control and PC3 
RNA was used as a negative control. There was no AR expression when P4E6 and BPH-
1 PPmO cells were grown in monolayer (Figure 3.13C and D). This agrees with the 
absence of AR protein determined by the western blot (Figure 3.9). There is a 
statistically significant increase of AR expression in P4E6 spheroids and BPH-1 PPmO 
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spheroids when grown without calcium in comparison to monolayer cells (One way 
ANOVA with a Dunnett’s multiple comparisons test, p=0.0488 and p=0.0421 
respectively) (Figure 3.13C and D). However there is no statistically significant 
difference in AR expression in P4E6 spheroids and BPH-1 PPmO spheroids when 
grown with calcium in comparison to monolayer cells (One way ANOVA with a 
Dunnett’s multiple comparisons test, p=0.3540 and p=0.8604 respectively) (Figure 
3.13C and D). Hence, in further experiments both P4E6 and BPH-1 PPmO spheroids 
were not grown in calcium. Detection of AR expression confirmed the utility of this 
model to study differentiation.  
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Figure 3.13: Growing cells into spheroids induces the expression of AR without the 
presence of calcium. (A) Representative images of P4E6 and BPH-1 PPmO spheroids, with 
and without calcium, to induce differentiation. (B) Percentage of mOrange expressing 
spheroids grown with and without calcium after 7 days. Two tailed unpaired t-test, * = p ≤ 
0.05 and ns = p>0.05. Error bars represent standard error of the mean. (C and D) Fold 
difference in AR expression between monolayer cells to spheroids grown for 7 days with and 
without calcium using qRT-PCR. AR expression is relative to the endogenous control RPLPO 
and normalised to PC3, the calibrator sample. One way ANOVA with a Dunnett’s multiple 
comparisons test, * = p ≤ 0.05 and ns = p>0.05. Error bars represent standard deviation 
calculated from the coefficient of variation. 
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3.2.4.2 AR expression is reduced in ARKO clones  
Once the method to form differentiated spheroids had been optimised in WT cells, 
the process was then repeated with ARKO clones. This was to confirm whether AR had 
been successfully knocked-out by CRISPR/Cas9. Subsequently, the extent of 
differentiation could then be investigated.  
ARKO clones were grown to form spheroids in the absence of calcium. This 
demonstrates that AR KO does not affect spheroid formation and are able to retain 
the same yield as WT spheroids. They were then collected and their RNA was 
extracted. qRT-PCR was then performed and the ΔΔCt method was used, to measure 
spheroid induced AR expression in comparison to WT spheroids. The primers were 
found in exon 9. Monolayer LNCaP and PC3 RNA were used as the positive and 
negative controls respectively. Whilst there was a decrease in AR expression in BPH-1 
PPmO ARKO clones (ARKO13 and ARKO19) it was not statistically significant (One way 
ANOVA with a Dunnett’s multiple comparisons test, p=0.0575 and p=0.1070 
respectively) (Figure 3.14A). This is likely due to the large variance in the data. There 
was a statistically significant decrease in AR expression in the P4E6 clone ARKO15 but 
not in the P4E6 clone ARKO22 (One way ANOVA with a Dunnett’s multiple 
comparisons test, p=0.0114 and p=0.8744 respectively) (Figure 3.14B).  
When calculating the relative expression of AR to RPLPO it became clear how 
important it is to choose an appropriate endogenous control. Three endogenous 
controls were tested due to large variation between the WT and ARKO clones. The 
BPH-1 PPmO cell line had the largest variation between monolayer cells and 
spheroids, as well as between WT spheroids and ARKO spheroids (see appendix 1.2). 
However the qRT-PCR results still showed an overall reduction in AR expression in 
ARKO clones which agrees with the nucleotide and protein sequence changes created 
by the CRISPR/Cas9.  
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Figure 3.14: AR expression is reduced in CRISPR/Cas9 AR KO clones. qRT-PCR was used 
to determine AR expression in BPH-1 PPmO WT and ARKO clone spheroids (ARKO13 and 
ARKO19) (A) and P4E6 WT and ARKO clone spheroids (ARKO15 and ARKO22) (B). AR 
expression is relative to the endogenous control RPLPO and normalised to PC3, the calibrator 
sample. One way ANOVA with a Dunnett’s multiple comparisons test. , * = p ≤ 0.05 and ns = 
p>0.05. Error bars represent standard deviation calculated from the coefficient of variation. 
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3.3 Characterising Differentiated ARKO Clone Spheroids  
3.3.1 Cell viability assay optimisation  
In order to verify whether knocking out the AR gene disrupts the cell viability and if 
there were any differences between clones, the CellTiter-Glo® assay (Promega) was 
used with WT BPH-1 PPmO and P4E6 spheroids in co-culture. The assay works by 
using ATP released from viable cells to convert luciferin to oxyluciferin. This then 
releases a luminescent signal which then can be detected and quantified. The assay 
has an upper limit of detecting 10 M before the sensitivity and reliability of the 
results diminish. Therefore, preliminary experiments were performed to determine the 
number of cells seeded in co-culture that produces less than 10 M of ATP. A standard 
curve of 50 M – 16 nM ATP was generated and using the equation of the line (y = 
3524.2x + 9358.9) the concentration of ATP released was calculated from the average 
luminescence. This was performed for WT BPH-1 PPmO and P4E6 spheroids in 
triplicate, at three different cell densities: 5,000, 10,000 and 15,000.  
All cell densities in both cell lines produced over 10 M ATP i.e. the detection limit of 
the assay (Figure 3.15). BPH-1 PPmO cells produced a relatively constant amount of 
ATP despite the difference in cell seeding densities. 5,000 BPH-1 PPmO cells produced 
the highest amount of ATP at 18.1 M compared to 15,000 cells at 12.4 M and 10,000 
cells at 14.1 M ATP. 10,000 P4E6 cells produced the most ATP at 27.8 M and 15,000 
P4E6 produced 16.9 M. 5,000 P4E6 cells produced the least amount of ATP at 11.9 
M. This assay requires further optimisation in order to determine a cell density at 
which to seed BPH-1 PPmO and P4E6 cells to ensure they produce less than 10 M 
ATP (Figure 3.15).  
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Figure 3.15: Optimisation of the CellTiter-Glo® assay. WT BPH-1 PPmO and P4E6 cells were 
seeded at different densities in co-culture with stroma to form spheroids. CellTiter-Glo® 
reagent was added after 1 week to test for cell viability and ATP concentration was measured.  
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3.3.2 Spheroid morphology and structure varies between cell lines 
The effect of ARKO on the structure and morphology of spheroids was investigated. 
After growing spheroids for 7 days they were imaged (Figure 3.16). Overall BPH-1 
PPmO spheroids were irregular in shape, more prone to form aggregates and less 
smooth than P4E6 spheroids. Aggregates were defined as when spheroids lacked 
distinct structure and had to have merged with many other cells. ARKO13 and 
ARKO19 had to be smaller than the BPH-1 PPmO WT and lentivirus control (Table 3.2 
and Figure 3.16). Conversely ARKO15 and ARKO22 were larger than the P4E6 WT and 
lentivirus control (Table 3.2 and Figure 3.16). All types of spheroids had 
heterogeneous morphology within and between experiments. 
Table 3.2: Summary of spheroid morphology in BPH-1 PPmO and P4E6 WT and ARKO 
clones.  
 
Cell type 
Size in 
comparison to 
WT 
Shape Smooth Aggregates 
B
P
H
-1
 P
P
m
O
 
WT / Irregular No Yes 
Lentivirus control Similar Irregular No Yes 
ARKO13 Smaller Irregular No Yes 
ARKO19 Smaller Irregular  No Yes 
P
4
E
6
 
WT / Spherical Yes No 
control Similar Spherical Yes No 
ARKO15 Larger Spherical Yes No 
ARKO22 Larger Spherical Yes No 
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Figure 3.16: Spheroid morphology is heterogeneous between cell lines and differs in 
ARKO clones. Representative images of BPH-1 PPmO and P4E6 WT, lentivirus control and 
ARKO clone spheroids after 7 days. Scale bar = 200μm. 
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3.3.3 Optimisation of AR and NKX3.1 IHC antibodies  
Prior to investigating the extent of differentiation in WT and ARKO spheroids, the 
antibodies for AR and NKX3.1 were optimised for IHC. Spheroids were then 
embedded in paraffin and sliced onto slides. The NKX3.1 antibody was provided by 
Cell Signalling (D6D2Z) and was tested with range of dilutions (1:500, 1:250 and 1:100) 
on patient derived BPH tissue. All concentrations resulted in a positive signal in the 
nucleus of luminal cells and hence the lowest dilution 1:500 was used in further 
experiments (Figure 3.16B). It is important to note that the antibody is specific to the 
columnar luminal cells that line the lumen (black arrow Figure 3.17B) and there is no 
signal seen in the thin basal layer underneath the luminal cells (blue arrow Figure 
3.17B).  
A variety of AR antibodies were tested (N20, C19 and 441 all provided by Santa-Cruz) 
with a range of dilutions (1:1000, 1:800, 1:500 and 1:200) on LNCaP cells as well as WT 
BPH-1 PPmO and P4E6 spheroids embedded in paraffin (Figure 3.17A). Both N20 and 
C19 antibodies stained the background of WT BPH-1 PPmO and P4E6 spheroids as 
well as the spheroids themselves but was gave a positive stain in LNCaP embedded 
cells. LNCaP cells stained with the N20 antibody had the strongest positive signal. The 
441 antibody did not stain the background or the spheroids but there is a signal seen 
in the LNCaP cells (black arrow Figure 3.17A). The 441 antibody was used in further 
experiments due to the lack of non-specific binding to the background of embedded 
spheroids. However none of the antibodies tested were optimal therefore more 
specific AR antibodies need to be investigated. 
  
108 
 
Figure 3.17: Optimisation of AR and NKX3.1 antibodies for IHC. (A) Three different AR 
antibodies (N20, C19 and 441) were tested at 1:200 dilution on paraffin embedded BPH-1 
PPmO WT spheroids, P4E6 WT spheroids and LNCaP cells. Black arrows indicate positive AR 
expression in LNCaP cells. (B) NKX3.1 antibody tested at 1:500 dilution on BPH tissue. Black 
arrow indicates positive AR expression in luminal cells. Blue arrow indicates negative AR 
expression in basal cells. Scale bar = 50 μm. 
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3.3.4 BPH-1 PPmO and P4E6 spheroids display heterogeneous 
expression of differentiation markers  
Despite confirming with qRT-PCR and the detection of mOrange that spheroids are 
able to induce differentiation of basal cells, this needed to be confirmed on the 
protein level. The spheroids were collected and embedded in paraffin as described 
previously. IHC was then conducted to test the presence and location of basal markers 
(CK5 and p63) and luminal markers (CK18, AR, NKX3.1). The antibodies for CK5, p63 
and CK18 were previously optimised in our lab. The expression levels of the 
differentiation markers are summarised in Table 3. Highest levels of expression are 
denoted +++, medium levels of expression are denoted ++, low levels of expression 
are denoted + and no expression is denoted -.   
All of the spheroids had low levels of expression for the early luminal marker CK18 
(Figure 3.19). None of the spheroids expressed the advanced differentiation markers 
NKX3.1 and AR (Figures 3.21 and 3.22). P4E6 lentivirus control spheroids did not 
express any basal markers (CK5 and P63) (Figures 3.18 and 3.19). They were also 
significantly smaller than when they were growing in MatrigelTM before embedding 
(Figure 3.16). P4E6 ARKO clones only expressed one of the basal markers (ARKO22 
expressed CK5 and ARKO15 expressed p63) and not both (Figures 3.18 and 3.19). All 
BPH-1 PPmO spheroids had high levels of expression both basal markers (Figures 3.18 
and 3.19).   
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Table 3.3: Expression levels of different differentiation markers in prostate spheroids  
 
Cell type CK5 p63 CK18 NKX3.1 AR 
B
P
H
-1
 P
P
m
O
 WT +++ ++ ++ - - 
Lentivirus control +++ +++ + - - 
ARKO13 ++ +++ - - - 
ARKO19 +++ +++ + - - 
P
4
E
6
 
WT +++ +++ + - - 
Lentivirus control - - + - - 
ARKO15 - ++ - - - 
ARKO22 ++ - + - - 
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Figure 3.18: Expression of CK5 in spheroids. IHC for CK5 expression in WT, lentivirus control 
and ARKO clones of BPH-1 PPmO and P4E6 spheroids. Scale bar = 50 μm. 
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Figure 3.19: Expression of p63 in spheroids. IHC for p63 expression in WT, lentivirus control 
and ARKO clones of BPH-1 PPmO and P4E6 spheroids. Scale bar = 50 μm. 
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Figure 3.20: Expression of CK18 in spheroids. IHC for CK18 expression in WT, lentivirus 
control and ARKO clones of BPH-1 PPmO and P4E6 spheroids. Scale bar = 50 μm. 
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Figure 3.21: Expression of NKX3.1 in spheroids. IHC for NKX3.1 expression in WT, lentivirus 
control and ARKO clones of BPH-1 PPmO and P4E6 spheroids. Scale bar = 50 μm. 
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Figure 3.22: Expression of AR in spheroids. IHC for AR expression in WT, lentivirus control 
and ARKO clones of BPH-1 PPmO and P4E6 spheroids. Scale bar = 50 μm. 
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3.3.5 AR is potentially required for differentiation  
mOrange fluorescence is used as a proxy for PSA expression, which only occurs in 
differentiated luminal cells due to the presence of AR. mOrange fluorescence  of BPH-
1 PPmO spheroids was quantified after 7 days of growth. Four random fields of view 
were chosen and each spheroid in every plane of view was categorised into either 
negative, dim or bright mOrange fluorescence (Figure 3.23A). Over half of spheroids 
do not express mOrange and hence do not differentiate in WT, control or ARKO 
conditions (Figure 3.23B). This indicates the difficulty of inducing differentiation in 
basal cell lines in 3D culture. Bright mOrange fluorescence was only seen in WT and 
lentivirus control spheroids (1.8% and 1.5% respectively). Dim mOrange fluorescence 
was seen in ARKO clones (ARKO13 and ARKO19) as well as WT and lentivirus control 
(Figure 3.23B). This is potentially due to the PSA-Probasin-mOrange promoter being 
leaky. Only bright mOrange represents differentiation and hence it could be 
suggested that AR might be for differentiation based upon this result. 
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Figure 3.23: AR is potentially required for differentiation in BPH-1 PPmO cells. The 
mOrange fluorescence of the BPH-1 PpmO spheroids in four random fields of view were 
counted in WT, lentivirus control and ARKO clones after 7 days. Each spheroid was categorised 
as either negative, dim or bright mOrange expression. (A) Representative images of negative, 
dim and bright mOrange fluorescence in BPH-1 PPmO spheroids. (B) mOrange fluorescence 
quantified in WT, lentivirus control and ARKO clones. Number of spheroids assessed ranged 
between 218-433, N= 3. 
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4. Discussion 
AR is vital for the development of the prostate as well as the proliferation and 
differentiation of prostate basal cells. Hence it is widely considered to be a master 
regulator. The research into how AR regulates differentiation of basal to luminal cells 
in both a normal and cancerous setting within the prostate is extensive. However, the 
majority of this research has been conducted on mouse prostate models or mouse 
and rat cell lines, which differ greatly from the human prostate (Lee et al., 2012, 
Simanainen et al., 2007, Whitacre et al., 2002, Wu et al., 2007). Therefore, the aim of 
this project was to explore the utility of the CRISPR/Cas9 system in order to create a 
permanent ARKO model in human basal cell lines. The role of AR in differentiation 
could then be investigated by culturing the ARKO cells in 3D to mimic differentiation 
of basal cells in vivo.  
4.1 CRISPR/Cas9 is a successful tool to generate gene KO 
models  
Prior to this project, CRISPR/Cas9 had never been used to KO AR in human prostate 
cell lines. Therefore the initial strategy was to test the efficiency of the CRISPR/Cas9 
lentivirus and optimise the work flow to generate single celled CRISPR/Cas9 edited 
clones. The work flow was initially optimised using BPH-1 cells because they are easily 
manipulated. Once it had been determined that the CRISPR/Cas9 was successful, the 
experiments were repeated on the differentiation models BPH-1 PPmO and P4E6 cells. 
The CRISPR/Cas9 lentivirus successfully transduced all three cell lines and genetic 
edits were detected in 30-59% of clones.  CRISPR/Cas9 was most efficient in P4E6 cell 
lines, despite the cell line being notoriously difficult to transduce. This is possibly due 
to P4E6 cells being the third cell line to undergo CRISPR/Cas9 KO of AR, and therefore 
the techniques and protocols had been optimised. In order to have the option to 
choose clones with the greatest genetic and amino acid changes, approximately 20 
clones were selected during dilution cloning. The online CRISP-ID tool enabled the 
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analysis of heterozygous KO clones in cell lines which had more than one copy of AR 
(Dehairs et al., 2016). However, it was limited to only producing three allele sequences, 
therefore next generation sequencing (NGS) could be used to have a more in depth 
view into the precise base changes in each copy.  
During the course of the project Wei et al. (2018) published a study in which they 
aimed to KO AR using CRISPR/Cas9 in LNCaP cells to investigate the role of AR on 
proliferation. They concluded that when AR is not present, proliferation decreases due 
to an increase in apoptosis. Since they lacked validation to prove AR was knocked-
out at the gene or protein level, these results must be interpreted with caution. They 
also did not produce single cell clones from their mixed population treated with 
CRISPR/Cas9 (Wei et al., 2018). Given only 30% of BPH-1 PPmO clones in this project 
were edited, the overriding phenotype within a mixed population would be BPH-1 
PPmO cells with genetically intact AR. Therefore it is vital to select single cell clones 
and characterise each one before conducting functional assays, which Wei et al. (2018) 
failed to do.  
One of the largest limitations of CRISPR/Cas9 is the occurrence of off-target effects. 
A recent study by Kosicki et al. (2018) has demonstrated that CRISPR/Cas9 can cause 
larger and more detrimental chromosomal changes than expected. They discovered 
that chromosomal translocations can occur, as well as inversions and deletions, 
ranging from 11 bp to 2.5 Kb. It also became apparent that there was a large range in 
the size of deletions at the target site, with over 20% of clones bearing deletions 
greater than 250 bp (Kosicki et al., 2018). In comparison, the clones in this project had 
deletions ranging from 1 bp to 58 bp. However, clone ARKO19 had an insertion of 
approximately 286 bp across the multiple alleles. It would therefore be useful in the 
future to sequence further afield from the target gRNA site to asses if the chosen 
clones in this project had any other genetic abnormalities. However, this project was 
focused on knocking-out the AR gene which is over 186 Kb long. Therefore, it is 
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unlikely that large chromosomal rearrangements in the AR gene sequence would have 
a substantial effect on other genes.  
To conclude, CRISPR/Cas9 was a relatively simple and easy to use tool which enabled 
the creation of multiple AR gene KO models. The generation of a sufficient number 
of single cell clones was laborious, but essential to produce clones with a 
homogenous phenotype. CRISPR/Cas9 was efficient in producing genetic edits in a 
range of cell lines, but it was most successful in P4E6 cells. However, the largest 
limitation of CRISPR/Cas9 is the presence off-target genetic edits and their unknown 
effects. Whole genome sequencing is the only way to elucidate the effects which 
would be costly and time consuming, but essential. However, the production of 
multiple clones can partially control for off-target effects.  
4.1.1 Therapeutic relevance of CRISPR/Cas9 
CRISPR/Cas9 has become a powerful genetic engineering tool to aid cancer research.  
Since its first use in 2013, it has rapidly spread across the scientific community, and 
has been adapted for a range of applications. It has now been used to investigate all 
ten hallmarks of cancer as described by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011, Moses et al., 2018). In the near future, CRISPR technology could be 
used in the clinic. Recently CRISPR/Cas9 has been used to modify chimeric antigen 
receptor (CAR) T-cells which are designed to target and destroy cancer cells 
(Schumann et al., 2015). Phase I clinical trials are currently being conducted in USA 
and China (Weidong, 2018). CRISPR/Cas9 has also been used to induce gene knock-
outs in both mouse and cell line models to help investigate PCa (Kawamura et al., 
2015, Takao et al., 2018, Ye et al., 2017). In particular, Ye et al. (2017) discovered that 
blocking GPRC6A by CRISPR/Cas9 suppressed prostate carcinogenesis in a xenograft 
model (Ye et al., 2017). Combined with my project demonstrating the efficiency of 
CRISPR/Cas9 in prostate human cell lines, it could be the start of discovering a novel 
gene therapy to treat PCa and CRPC using CRISPR/Cas9. 
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4.2 The role of AR in the prostate epithelium  
4.2.1 AR may be required for differentiation  
In order to measure basal to luminal cell differentiation, an existing model was used 
in this study. The induction of mOrange in the BPH-1 model system used is regulated 
by the PSA-Probasin promoter. PSA is a luminal marker and is regulated by AR, 
therefore the rationale is that AR must be present in order for mOrange expression to 
be induced (Kim and Coetzee, 2004). However, only 2% of WT and lentivirus control 
BPH-1 PPmO spheroids expressed bright mOrange. This is a small percentage of cells, 
and so in some ways the readout is not optimal. The lack of AR detected in sectioned 
WT spheroids via IHC is therefore likely due to both a combination of an ineffective 
antibody and the largest proportion of spheroids not expressing AR. Once a suitable 
antibody has been optimised, in the future it would be necessary to section the entire 
paraffin block to search for the 2% of differentiated spheroids. Nevertheless no ARKO 
clone had any spheroids that were positive for very bright mOrange, and so the 
implication is that less differentiation occurred in these clones compared to the WT. 
Both WT and ARKO BPH-1 PPmO spheroids display dim mOrange fluorescence after 
seven days in culture. This could be indicative of differentiation, but the complete lack 
of bright mOrange expression in ARKO clones could suggest dim mOrange 
fluorescence occurs due to a leaky promoter. This is defined as low level transcription 
occurring during the inactive state (in the absence of a stimulus) of the promoter 
(Huang et al., 2015, McCutcheon et al., 2018). This phenomenon is seen classically 
with the lac operon, whereby there is a low level of expression of lac promoter control 
genes even when lactose is not present (Jacob and Monod, 1961). Previous research 
done in our lab also supports this idea, as Pellacani et al (2014) noted that 50% of 
spheroids had detectable levels of mOrange, but AR was only found in a rare 
subpopulation of cells (Pellacani et al., 2014). This is a limitation to the BPH-1 PPmO 
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model, and perhaps detection of differentiation markers via IHC is a more reliable 
indicator for the occurrence of differentiation.  
The qRT-PCR results demonstrated that AR expression was reduced in BPH-1 PPmO 
ARKO clones in comparison to WT and control spheroids, which was encouraging. 
However, some AR expression was still detected in ARKO clones, which contradicts 
the absence of mOrange fluorescence. This could possibly be due to not all three 
copies of AR in BPH-1 PPmO ARKO clones being inactive. Also, it is likely that mRNA 
is still produced by ARKO spheroids which can be detected by the qRT-PCR, but the 
full AR protein would not be formed. Therefore to validate the KO of AR, further 
protein analysis will need to be done in the future. Also again, the low amount of AR 
expression pushes the sensitivity of the qRT-PCR method. The limitation of using the 
ΔΔCt method for small changes in gene expression is that it requires a stable 
endogenous control for comparison. Three different endogenous controls were 
tested (Appendix 1.1), but expression varied up to 4.81 Ct values between conditions 
(Appendix 1.2). Primer efficiencies were also over 110%, and according to MIQE 
guidelines this could be due to primer-dimers or nonspecific amplicons. This could 
also explain why clone ARKO22 did not show a reduction in AR expression, despite 
amino acid sequence alignment predicting it has the shortest amino acid sequence of 
AR after CRISPR/Cas9 causing a frame shift mutation. Therefore selection of an 
endogenous control specific to the experimental conditions is important. The ΔΔCt 
method might not be sufficiently sensitive enough to detect the low level of AR mRNA 
expression. Alternatively, absolute levels of AR mRNA could be determined by 
creating a standard curve of known copies of AR plasmid DNA. This method for qRT-
PCR does not require an endogenous control and would be more sensitive to 
expression levels.  
The formation of prostate spheroids enables researchers to replicate what occurs in 
vivo without the use of mouse models (Adcock et al., 2015). In our lab they have been 
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used as a method to induce differentiation (Maitland et al., 2001, Pellacani et al., 2014). 
However this is extremely difficult to achieve due to the challenge of growing luminal 
cells in culture (Chua et al., 2014). There is a large range of 3D structures described by 
different authors which makes comparisons extremely difficult (Bello-DeOcampo et 
al., 2001, Brinkmann et al., 1995, Kogan et al., 2006, Lang et al., 2006, Miki et al., 2007, 
Webber et al., 1997). During the project we also identified variation in spheroid 
structure between experiments (not shown). Perhaps a different method of forming 
the spheroids would result in greater differentiation rates and more consistent 
phenotypes. For example, a therapeutic screening study of 3D tumour spheroid 
models found that the pellet culture method used with rabbit bone marrow derived 
mesenchymal progenitor cells produced the highest amount of spherical spheroids in 
comparison to other methods (magnetic levitation, hanging drop method and 
rotating wall vessels) (Johnstone et al., 1998, Zanoni et al., 2016).  
Previous work on keratinocytes demonstrated a “calcium switch” induced 
differentiation. In particular, low calcium (0.03-0.1 mM) prevented the keratinocytes 
from differentiating, whereas growth in high calcium (0.1-1.4 mM) resulted in the 
formation of differentiated suprabasal epidermal cells (Boukamp et al., 1988, 
Hennings et al., 1980, Pillai et al., 1990). Therefore, to test if the same effect occurs in 
prostate cell lines, BPH-1 PPmO and P4E6 WT spheroids were grown in high calcium 
(2 mM) for 7 days. A particularly high concentration of calcium was chosen to induce 
the rate of differentiation as greatly as possible. Initially calcium increased the rate of 
differentiation but by day 7 there was no difference in the number of mOrange 
fluorescing spheroids grown with and without calcium. AR expression was also 
significantly greater when the spheroids were grown without calcium. Perhaps the 
level of calcium was too high and had an inhibitory effect on terminal luminal 
differentiation in both BPH-1 and P4E6 cells. Work by Tyson et al. (2007) 
demonstrated that different prostate cell lines form acini in a range of different 
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calcium concentrations (Tyson et al., 2007). Therefore, the effect of calcium on 
differentiation is cell line specific and it can also be found to inhibit lumen formation. 
The required calcium concentration for optimum differentiation needs to be further 
investigated. Also the timing at which calcium is added to the media needs to be 
investigated as it could also have an effect on the rate and extent of differentiation. It 
is likely that this will vary between the BPH-1 PPmO spheroids and P4E6 spheroids.   
In summary, IHC and qRT-PCR are not sufficiently sensitive enough methods to allow 
the detection of the rare population of differentiated spheroids. Flow cytometry would 
be the next best candidate to help detect the 1-2% of spheroids which differentiate 
and express AR. A combination of an AR antibody and detection of mOrange would 
help count the number of differentiated BPH-1 PPmO cells. This method would also 
enable counting of differentiated P4E6 cells which was not possible in this study. 
However, a method to disaggregate spheroids to avoid doublets would need to be 
optimised. Also, as discussed in section 4.2.2, terminally differentiated luminal cells 
also undergo apoptosis, and therefore it is imperative that the media is collected in 
order to detect these cells.  
4.2.2 Terminally differentiated luminal cells undergo apoptosis  
Previously, the induction of an epithelial bilayer by allowing cells to grow to be over 
confluent was only attempted in primary cell cultures (Frame et al., 2010, Swift et al., 
2010). Here, this method for inducing differentiation was attempted with BPH-1 and 
BPH-1 PPmO cells, using mOrange as an indicator for luminal differentiation. Initially 
it appeared via fluorescence imaging that BPH-1 PPmO cells which formed a bilayer 
had differentiated into luminal cells. However, when this was quantified by flow 
cytometry there was half the number of mOrange expressing cells when grown in a 
bilayer than when grown at 80% confluent monolayer. This discrepancy could be due 
to the terminally differentiated luminal cells undergoing apoptosis and being 
aspirated during cell collection for flow cytometry (Chen et al., 2016, Pellacani et al., 
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2014). This has been previously identified by Pellacani et al. (2014) whereby 80% of 
the spheroids contained cells undergoing apoptosis within the centre of spheroid, 
highlighting the instability of differentiated cells (Pellacani et al., 2014). Also, viability 
dye was not used, which would have been used to gate out dead cells. It has also been 
observed in our lab that BPH-1 cells are able to undergo spontaneous differentiation 
during monolayer cell culture. This could explain the presence of differentiated 
luminal cells while in normal monolayer culture.  However, relying on spontaneous 
differentiation was insufficient for detection of AR via western blot or qRT-PCR and 
hence the basal cells were differentiated using 3D culture.  
4.2.3 AR is not required for basal cell survival  
The ability to grow ARKO clones in normal cell culture as well in 3D spheroids, 
indicates that AR is not essential for basal cell survival. This phenomenon has been 
discovered in other studies. Xie et al (2017) conditionally deleted AR in mouse basal 
cells, and Caspase 3 staining showed there was no change in apoptosis in the absence 
of AR (Xie et al., 2017). Lamb et al (2010) also agrees and concluded that differentiated 
secretory luminal cells required cell-cell adhesion via e-cadherin for survival rather 
than androgen activity or keratin growth factor (KGF) released from the stroma (Lamb 
et al., 2010).  
In an attempt to confirm that ARKO does not affect cell viability, the CellTiter-Glo® 3D 
cell viability assay was performed. The assay was initially attempted to be optimised 
for the number of seeded cells required to produce ATP below the detection limit. 
The number of cells that produced the maximum concentration of ATP differed 
between cell lines. This is likely due to the difference in structure, size and shape 
between P4E6 and BPH-1 PPmO spheroids affecting the uptake of the CellTiter-
Glo® reagent. ATP detected from BPH-1 PPmO spheroids decreased when the 
number of cells seeded increased. This is likely due to BPH-1 PPmO spheroids forming 
larger aggregates and hence making it more difficult for the CellTiter-Glo® reagent to 
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penetrate. Mixing the reagent and cells more vigorously and for longer would 
improve this assay. In the future, sections of WT and ARKO clones could be stained 
for Caspase 3 to measure the rate of apoptosis in the absence of AR.  Alternatively, 
colorimetric viability assays could be performed such as the MTS or MTT assays 
(abcam). Differentiation of basal cells could also result in a change in cellular 
metabolism. Therefore detection of ATP could be misleading for cell viability and 
instead the spheroids could be disaggregated and the number of cells could be 
directly counted using a haemocytometer or an automated cell counter.  
4.2.4 Identification of AR splice variants  
Alternative splicing of AR results in several AR splice variants (ARVs). The majority of 
ARVs lack the LBD, and hence this allows the development of CRPC in PCa cells treated 
with ADT. Initial differentiation experiments involved incubating BPH-1 WT and BPH-
1 ARKO cells in DHT for 24 hr. The presence of AR protein was then detected via a 
western blot. Full length AR was detectable at 110 kDa only in the positive control, 
VCaP cells (Figure 3.10). However, there are multiple bands seen at lower molecular 
weights which could be different ARVs. VCaP cells have over 35 copies of AR, resulting 
in high AR expression which is not representative of normal physiological levels 
(Figure 3.1). Therefore, detection of low levels of AR from WT BPH-1 and P4E6 cells 
could be missed. To rectify this, VCaP protein lysate could be diluted down to match 
the levels of AR expression in BPH-1 and P4E6 cells (approximately 1 in 35). 
Alternatively, patient BPH-1 tissue lysate could be used as the positive control.  
The WT BPH-1 and two ARKO clones produced a single band on western blotting at 
approximately 65 kDa. In general, the band was only seen when DHT was not present 
and therefore DHT could be suppressing the presence of the ARV. The epitope for the 
antibody used on the western blot is to the LBD, which rules out the majority of the 
ARVs. However, a likely candidate for the band is the ARV, AR45 which has been found 
to be 67kDa in mouse muscle (Ma et al., 2015). Conversely, it has been found in heart 
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extracts cells to be 45 kDa (Ahrens-Fath et al., 2005). This splice variant is not very well 
characterised and it has never been detected in BPH-1 cells. To confirm the presence 
of AR45 and other ARVs, qRT-PCR specific to different ARVs could be performed. 
Another candidate for the lower band is the presence of Albumin (a common 
contaminant) at 68 kDa, which would indicate the western blot protocol requires 
optimisation. Alternatively, the band could be due to non-specific binding and a more 
specific AR antibody is required.  
4.3 Immortalisation of cell lines results in genomic 
instability  
AR is located on the X chromosome and hence healthy human males only possess 
one copy. However, in CRPC patients AR can be amplified as a mode of resistance to 
ADT (Visakorpi et al., 1995). Therefore, the presence of AR amplification and number 
of X chromosomes (and hence number of copies if AR) was investigated in BPH-1, 
BPH-1 PPmO and P4E6 cell lines. The malignant and androgen-independent cell line 
VCaP was used as a control as it has been previously characterised that VCaP cells 
have undergone AR amplification (Li et al., 2012, Taurozzi, 2016). The original 
karyotype of BPH-1 cells produced by Hayward et al. shows that BPH-1 cells had two 
X chromosomes and hence it was predicted they would have two copies of AR 
(Hayward et al., 1995). This was confirmed by the copy number analysis conducted 
during this project. The inflation of the number of X chromosomes is likely caused by 
genetic instability during the immortalisation process. BPH-1 cells are immortalised 
by the common method of transfection with the SV40 virus large T antigen (LT). 
However, LT is well known to induce genomic instability resulting in chromosomal 
structural abnormalities and the generation of aneuploidy in cell lines (Ray et al., 1990, 
Stewart, 1991, Woods et al., 1994). BPH-1 PPmO cells on the other hand contained 
three X chromosomes and copies of AR. Perhaps subsequent transduction of BPH-1 
with a lentivirus containing the reporter gene PSA-Probasin mOrange could have 
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resulted in further genomic instability. This is an important observation, and one that 
suggests that such genetically manipulated models may have unforeseen changes. 
For example, the C4-2 cell line is a metastatic derivative of the LNCaP cell line. 
However genome and exome sequencing has shown 2056 specific mutations to the 
C4-2 cell line, which provides evidence for the significant genetic changes which can 
occur between two related cell lines.  
P4E6 cells on the other hand only contained one X chromosome and a single copy of 
AR, which agrees with the results produced by Taurozzi (2016). The lack of X 
chromosome amplification could be due to the difference in immortalisation methods 
between P4E6 cells and BPH-1 cells. P4E6 cells were immortalised by HPV16 E6 
retrovirus, which has been demonstrated in keratinocytes to upregulate telomerase 
hTERT gene transcription and activity, as well as degrading the tumour suppressor 
p53 (Klingelhutz et al., 1996, Maitland et al., 2001, Scheffner et al., 1990). The ability 
to maintain the length of the telomeres will aid the genomic stability. SV40 LT on the 
other hand does not maintain telomere length but blocks retinoblastoma protein, 
which results in excessive cell growth (DeCaprio et al., 1988). These two factors 
combined probably results in the large amount of genomic instability caused by the 
LT protein. Also, BPH-1 were at a higher passage than P4E6, which could also be a 
contributing factor to their greater genomic instability and aneuploidy. 
4.4 Future work and concluding remarks  
The generation of an ARKO model was successful in human basal cell lines using 
CRISPR/Cas9. This is the first time that several ARKO clones have been generated in 
human basal cell lines within the field. However, as demonstrated by the copy number 
analysis, the immortalisation of cell lines results in genomic instability. Hence, to 
create a better model for the role of AR in the human prostate, CRISPR/Cas9 KO of 
AR could be conducted on human primary cells in the future (Figure 4.1B).  
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From the results of this project it can be inferred that AR is required for differentiation. 
However, differentiated spheroids were rare and the PSA-Probasin mOrange 
promoter is suspected to be leaky. To optimise the differentiation of spheroids, RA 
could be added to the differentiation media as it has been found previously to be 
important in the development of the prostate alongside androgens (Figure 4.1A) 
(Bryant et al., 2014). To further induce differentiation, the next step would be to 
engraft P4E6 and BPH-1 PPmO WT and ARKO clones into mice with stromal 
fibroblasts (Figure 4.1C). Hayward et al. (2001) has also demonstrated that BPH-1 cells 
can initiate tumour growth when recombined with CAFs (Hayward et al., 2001). It 
would then also be possible to investigate the role of AR in tumorigenesis by 
engrafting BPH-1 PPmO ARKO clones along with CAFs into mice.  
Overall, the extensive characterisation of CRISPR/Cas9 generated ARKO clones will 
allow further investigation into the role of AR during the development of PCa. This 
could help further elucidate the mechanisms by which CRPC occurs in order to design 
more effective treatments. 
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Figure 4.1: Proposed future experiments to determine the role of AR during epithelial 
differentiation.  (A) Addition of RA along with the existing differentiating factors (DHT and β-
estradiol) during the growth of WT and ARKO spheroids. (B) KO AR in basal primary cells using 
CRISPR/Cas9 and select with puromycin. The heterogeneous population of cells would be left 
to become over confluent to investigate if a differentiated epithelial bilayer would form. (C) 
Implant WT and ARKO clones into mice and extract the differentiated cyst after 1-2 months. 
Analyses the cyst for differentiation markers via IHC and qRT-PCR, and total gene expression 
changes via RNASeq.  
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Appendix 
 
Appendix 1.1 qRT-PCR Ct values generated from different endogenous controls 
 Cell Type RPLPO HPRT RSP27A 
B
P
H
-1
 P
P
m
O
 
Monolayer WT 19.55 22.94 22.03 
WT Spheroid +Ca 22.63 25.67 24.7 
WT Spheroids –Ca 24.36 27.12 26.29 
ARKO13 Spheroid 21.39 23.97 23.54 
ARKO19 Spheroid 22.06 24.88 24.07 
P
4
E
6
 
Monolayer WT 21.41 25.65 23.42 
WT Spheroid +Ca 22.33 26.13 24.12 
WT Spheroids –Ca 21.76 25.52 23.15 
ARKO15 Spheroid 21.08 25.84 23.19 
ARKO22 Spheroid 21.81 28.16 23.74 
 
 
Appendix 1.2 Range of Ct values generated from different endogenous controls 
 
RPLPO HPRT RSP27A 
BPH-1 PPmO 4.81 4.18 4.26 
P4E6 1.25 2.64 0.97 
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Appendix 2.1 Sequences of BPH-1 clones targeted with AR CRISPR/Cas9 
lentivirus. Yellow arrow indicates the start of the edit site.  
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Appendix 2.2 Sequences of BPH-1 PPmO clones targeted with AR CRISPR/Cas9 
lentivirus. Yellow arrow indicates the start of the edit site.  
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Appendix 2.3 Sequences of P4E6 clones targeted with AR CRISPR/Cas9 
lentivirus. Yellow arrow indicates the start of the edit site.  
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Abbreviations 
3D-CRT 3D-dimensional conformal radiation therapy 
ADT Androgen deprivation therapy  
ALDH Aldehyde dehydrogenase  
APES 3-aminopropyltriethoxysilane  
AR Androgen receptor  
ARE Androgen response elements 
ARVs AR splice variants  
ATCC American type culture collection  
ATP Adenosine triphosphate  
BM Basement membrane  
bp Base pairs 
BPH Benign prostatic hyperplasia  
CaCl2  Calcium chloride  
CAFs Carcinoma associated fibroblasts  
147 
CAR Chimeric antigen receptor  
CARNs Castration resistant NKX3.1 expressing cells  
CB Committed basal cells 
cDNA Complementary DNA 
CRPC Castration-resistant prostate cancer  
crRNAs Crispr RNA 
CSC Cancer stem cell  
CT Threshold cycle 
D10 DMEM + 10% FCS + 2 mm L-Glutamine 
DAB Diaminobenzidene 
DAPI 4′,6-diamidino-2-phenylindole 
DBD DNA binding domain  
dCas9 “dead” Cas9  
DHT Dihydrotestosterone 
DMEM Dulbecco’s modified eagle’s medium 
148 
DMS Dimethyl sulfoxide  
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DSB Double stranded break 
EBRT External beam radiation therapy  
ECL Enhanced chemiluminescence 
ECM Extracellular matrix  
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor  
EMT Epithelial-to-mesenchymal transition  
FCS Foetal calf serum 
FGF Fibroblast growth factor  
g Gram 
gDNA Genomic DNA  
GnRH Gonadotropin-releasing hormone  
149 
gRNA Guide RNA  
HDR Homology-directed repair  
HIER Heat-induced epitope retrieval  
HIFU High-intensity focused ultrasound  
HR Hour 
HRP Horseradish peroxidase 
Hsp Heat shock proteins  
ICC Immunocytochemistry 
IGF Insulin-like growth factor  
IHC Immunohistochemistry 
IMRT Image-guided intensity-modulated radiation therapy  
K2 KSFM media + 2% FCS + 2 mm L-Glutamine + BPE + EGF 
kDa Kilo dalton 
KGF Keratin growth factor  
KO Knock-out  
150 
KSFM Keratinocyte serum-free medium 
LBD Ligand-binding domain  
LHRH Luteinising hormone releasing hormone  
LT Large T antigen  
M Molar  
mg Milligram 
MgCl2 Magnesium chloride 
min Minute 
ml Millilitre 
mM Millimolar 
mRNA Messenger RNA 
NE Neuroendocrine 
ng Nanogram 
NHEJ Non-homologous end joining  
nm Nanometre 
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NSE Neurone specific enolase 
NTD Transcriptional activation domain   
PAMs Protospacer adjacent motifs 
PAP Prostatic acid phosphatase  
PBS Phosphate buffered saline 
PCa Prostate cancer 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PIA Proliferative inflammatory atrophy  
PIN Prostatic intraepithelial neoplasia  
PSA Prostate specific antigen  
qRT-PCR Quantitative reverse-transcriptase PCR 
R10 RPMI + 10% FCS + 2 mm L-Glutamine 
R5 RPMI + 5% FCS + 2 mm L-Glutamine 
RA Retinoic acid  
152 
RAR RA receptor  
RARE Retinoic acid response elements 
RPM Revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
RT Reverse transcriptase 
RVD Repeat variable diresidue  
RXR Retinoic X receptors  
SC Stem cell 
T25 25cm2 tissue culture flask 
T75 75cm2 tissue culture flask 
TA Transit amplifying cells 
TALENs Transcription-activator-like effector nucleases  
TALEs Transcription-activator-like effectors  
TBST TBS + tween-20 
tracrRNA Trans-activating RNA 
153 
TRUS Transrectal ultrasound  
TURP Transurethral resection  
UGE Urogenital sinus epithelium  
UGM Urogenital sinus mesenchyme  
v/v Volume per volume 
w/v Weight per volume 
WT Wild type 
ZF Zinc finger  
ZFN Zinc finger nucleases  
β-Me β-mercaptoethanol 
μg Microgram 
μl Microlitre 
μm Micrometre 
μM Micromolar 
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